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INTRODUCTION 
 
 The development of a new drug molecule is a time consuming procedure 
and requires approximately 125 million dollars. This is beyond the scope of 
pharmaceutical companies in developing countries like India. But it is possible to 
give a new life to the existing molecules by formulating them in the form of novel 
drug delivery systems. Therefore, in recent years, considerable attention has been 
focused on the development of new drug delivery systems. The therapeutic 
efficacy and safety of the drugs administered by convention methods can be 
improved by more precise spatial and temporal placement within the body, 
thereby reducing both the size and number of doses through a controlled drug 
delivery. 
Rate Controlled Drug Delivery (Chein, 1998) 
 For many decades, medication of an acute disease or a chronic illness has 
been accomplished by delivering drugs to patients via various pharmaceutical 
dosage forms like tablets, capsules, pills, injectables, suppositories etc. as carriers. 
Though, these conventional drug delivery systems are still the primary 
pharmaceutical products, recently several advancements have been made towards 
development of new techniques of drug delivery. These techniques are capable of 
controlling the rate of drug delivery, sustaining the duration of therapeutic activity 
and/or targeting the delivery of drug to a tissue. The novel drug delivery systems 
would provide one or more of the following benefits: 
 Controlled administration of a therapeutic dose at a desirable delivery rate. 
 Maintenance of drug concentration within an optimal therapeutic range for 
 prolonged duration of treatment 
 Maximization of efficacy dose relationship 
 Reduction of adverse effects 
 Minimization of need for frequent dose intake 
 Enhancement of patient compliance 
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 Continuous i.v. infusion is recognised as the superior mode of drug 
administration as it bypass hepatic first pass metabolism and maintain constant & 
prolonged drug level in the body. However this type of administration involves 
certain risks & need for close medical supervision of drug administration, thus 
using skin as a port of drug entry i.v. infusion could be duplicated (Misra, 2004). 
 Transdermal is a route of administration wherein active ingredients are 
delivered across (trans) the skin (dermal) for systemic distribution. In a broad 
sense, the term TDDS includes all topically administered drug formulations 
(patch, ointment, cream, gel, specially formulated sprays, etc.) intended to deliver 
the active ingredient into the general circulation. In the past, the most commonly 
applied systems were topically applied creams & ointments for dermatological 
disorders.  
 Transdermal systems are ideally suited for diseases that demand chronic 
treatment such as cardiovascular diseases, which require prolonged medication & 
sometimes lifelong therapy is advised. The extensive vital research work of last 25 
years has generated around 10 marketed transdermal patches & a large number of 
patents. Commercially available transdermal patches are limited in number but 
this small group of marketed products represents many important classes: 
antianginal (Nitroglycerin, Isosorbide dinitrate), antihypertensive (Clonidine), 
antiemetics (Scopolamine), hormones (Estradiol, Testosterone), opioids 
(Fentanyl) and anticholinergics (Nicotine). 
Transdermal Patches (Sandhu Premjeet et al., 2011) 
 A transdermal patch or skin patch is a medicated adhesive pad (a flat 
mass of soft material used for protection, stuffing or comfort) that is placed on the 
skin to deliver a specific dose of medication through the skin into the bloodstream. 
 An advantage of a transdermal drug delivery route over other types of 
medication delivery such as oral, topical, intravenous, intramuscular, etc. is that 
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the patch provides a controlled release of the medication into the patient, usually 
through either a porous membrane covering a reservoir of medication or through 
body heat melting thin layers of medication embedded in the adhesive. 
 Theoretically, transdermal patches works in a very simple way. A drug is 
applied in a relatively high dosage to the inside of patch, which is worn on the 
skin for an extended period of time. Through a diffusion process, the drug enters 
the bloodstream directly though the skin. Drug is placed in large amount in the 
patches to keep the concentration gradient suitable for absorption because the 
active ingredients act at low dosage. Since there is high concentration on the patch 
and low concentration in the blood, the drug will keep diffusing into the blood for 
a long period of time, maintaining the constant concentration of drug in the blood 
flow. 
Benefits & Drawbacks of TDDS (Kamal Saroha et al., 2016) 
 There are some discomforts associated with TDDS but its advantages 
outweigh the discomforts. 
Possible discomforts of TDDS: 
 TDDS could be unsuitable for drugs that irritate or sensitize skin. 
 The natural limits of drug entry imposed by the skin’s permeability 
 indicate that only relatively potent drugs are suitable for transdermal 
 delivery. 
 Transdermal therapy is not feasible for ionic drugs. 
 It cannot deliver drug in pulsatile fashion. 
 Some drugs e.g. scopolamine transdermal patch placed behind the ear, it is 
 uncomfortable.  
 Long time adhere is difficult.  
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Advantages of TDDS: 
 The ease of usage makes it possible for patients to self-administer these 
 systems. 
 In case of an emergency, drug therapy can be terminated quickly by 
 removal of the application from the surface of the skin. 
 They are noninvasive, avoiding the inconvenience of parenteral therapy. 
 Provides ease of rapid identification of medication in non responsive 
 patients, unconscious or comatose patients. 
 They can avoid GIT difficulties during absorption caused by 
gastrointestinal pH, enzymatic activity & drug interaction with food, drink 
or any other orally administered drug. 
 Suitable in instances like vomiting or diarrhoea where oral route is not 
 desirable. 
 Since the composition of skin structurally and biologically is the same in 
almost all the humans, there is minimal inter & intra patient variation. 
 Hepatic first pass metabolism, salivary metabolism and intestinal 
 metabolism are avoided. 
 Extends the activity of drugs with short biological half-lives, which would 
otherwise require frequent dosing, through the reservoir of drug present in 
the delivery systems and its controlled release characteristics. 
 Due to reduced frequency of dosing there is better patient compliance. 
 Therapeutic failures associated with irregularities in the dosing with 
 conventional therapies can be avoided. 
 Less chance of over or under dosing as the result of prolonged 
 preprogrammed delivery of drug at the required therapeutic rate. 
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Table 1 Ideal properties of TDDS 
Properties Range 
Shelf life Should be up to 2.5 years 
Patch size Should be less than 40 cm2 
Dose frequency Once in a day - once in a week 
Appearance Should be clear or white in color 
Packaging properties Should be easily removable of release liner & have 
minimum number of steps required to apply 
Skin reaction Should be non-irritating & non sensitizing 
Release Properties Should have consistent pharmacokinetic & 
pharmacodynamic profiles over time 
 
Factors Affecting TDDS 
Biological factors 
 Skin condition: Acids and alkalies, many solvents like chloroform, 
methanol damage the skin cells and promotes penetration. Diseased state 
of patient alters the skin conditions. 
 Skin age: The young skin is more permeable than older. Children’s are 
more sensitive for skin absorption of toxins. 
 Regional skin site: Thickness of skin, nature of stratum corneum and 
density of appendages vary site to site. These factors affect significantly 
penetration. 
 Species Differences: The skin thickness, density of appendages and 
 keratinization of skin vary species to species, so affects the penetration. 
 Skin metabolism: Skin metabolizes steroids, hormones, chemical 
carcinogens and some drugs. So skin metabolism determines efficacy of 
drug permeated through skin. 
 Blood supply: Changes in peripheral circulation can affect transdermal 
 absorption. 
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Physicochemical factors 
 Temperature and pH: The drug permeation increases ten folds with 
temperature variation. The diffusion coefficient decreases as temperature 
falls. Weak acids and weak bases dissociate depending on the pH and pKa 
or pKb values. The proportion of unionized drug determines the drug 
concentration in skin.  
 Diffusion coefficient: Drug penetration depends on diffusion coefficient of 
drug. At a constant temperature the diffusion coefficient of drug depends 
on properties of drug, diffusion medium and interaction between them. 
 Drug concentration: The flux is proportional to the concentration gradient 
across the barrier and concentration gradient will be higher if the 
concentration of drug will be more across the barrier. 
 Skin hydration: In contact with water the skin permeability increases 
significantly. Hydration is the most important factor increasing the skin 
permeation. So humectants are used in transdermal delivery. 
 Partition coefficient: The optimal partition coefficient (K) is required for 
good action. Drugs with high K are not ready to leave the lipid portion of 
skin. Also drug with low K will not be permeated. 
 Molecular size and shape: Drug absorption is inversely related to 
 molecular weight. Small molecules penetrate faster than larger ones. 
Basic Components of Transdermal System (Mishra, 2004) 
 Following are the basic components which generally are used in the 
formulations of almost all type of transdermal patches. 
Drug 
 The drug, of which transdermal system will be designed, should possess 
some physicochemical characteristics. It will be in direct contact with the release 
liner. The structure of skin also affects skin penetration. Drugs, which are 
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efficacious in only a few milligrams per day, are considered as candidates for 
transdermal delivery. Pro-drugs can be used to reduce the melting point and 
change the partition coefficient of drugs so as to increase the permeation through 
the skin. The drug should be non- irritating and non-allergenic to human skin as 
very little can be done, if the drug is a strong irritant. 
Table 2 Ideal properties of drug for TDDS 
Properties Range 
Dose Should be low (generally <20mg/day) 
Elimination half life of drug in hour Should be 10 or less 
Molecular weight Should be less than 500 Dalton 
Partition Coefficient Log P (Octanol-Water) should be in the 
range of 1 to 3 
Drug reaction Should be non-irritating and non 
sensitizing 
Oral Bioavailability Should be low 
Therapeutic Index Should be low 
pH of saturated aqueous solubility 5-9 
 
Polymer matrix or matrices 
 Polymers are the foundation of transdermal system. The selection of 
polymer and design are of prime importance. Considerations for polymer selection 
in transdermal delivery system:  
 It should be stable and non-reactive with the drug moiety.  
 It should be easily available, fabricated and manufactured in to desired 
 formulations.  
 The properties of polymer e.g. molecular weight, glass transtition 
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temperature, melting point and chemical functionality etc. should be such 
that drug can easily diffused through it and with other components of 
system.  
 The mechanical properties should not change if large amount of drug 
 incorporate. 
 It should provide consistent release of drug throughout the life of system. 
Semi permeable (release) membrane 
 It takes place in reservoir type and multi-layer patch systems. These 
membranes control the rate of drug diffusion out of the patch and into the skin. 
Important properties to consider include the membrane composition and thickness. 
Adhesives 
 It serves to adhere the components of the patch together along with 
adhering the patch to the skin. Adhesive should enable the transdermal system to 
easily adhere to the skin and should not be irritant or allergen for skin. Generally, 
pressure-sensitive adhesives are used in transdermal systems.  
Backing layer 
 The backing is the outermost layer of the patch, which protects the system 
from external effects while the patch is worn and ensures integrity of the system in 
the storage period. For this purpose, the materials impermeable for drug molecule 
are used as backing layer. The backing layer must be inert and not compatible 
with the drug and other substances used in the formulation and it should have low 
water vapour transmission rate so as to promote skin hydration and thus greater 
skin permeability of drug. Important considerations include occlusivity, patient 
comfort and cosmetic appearance. 
Release liners 
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 Generally, patch is covered by protective liner during storage until it is 
used. The release liner protects the adhesives and drug formulations. It is removed 
prior to patch application. Ideally, it should be easily peeled from the adhesive 
layer and should not damage the structure of adhesive layer. Since release liner is 
in intimate contact with the transdermal system, it should be physically as well as 
chemically inert. The release liner is composed of a base layer which may be non-
occlusive (e.g. paper fabric) or occlusive (e.g. polyethylene, polyvinylchloride) 
and a release coating layer made up of silicon or Teflon. Important considerations 
when choosing a liner include: adhesive, drug formulations and release forces. 
Solvents 
 Various solvents are used to solve or disperse the polymer and adhesive or 
drug used in preparation of the transdermal systems.  
Plasticizers 
 Plasticizers are generally non-volatile organic liquids or solids with low 
melting temperature and when added to polymers, they cause changes in definite 
physical and mechanical characteristics of the material.  One of the many 
advantages of plasticizers used in transdermal formulations is the controlling of 
the release rate of therapeutic compound which can be done by the selection of the 
plasticizer type and the optimization of its concentration in the formulation.  
 The reasons for the use of plasticizers in transdermal drug delivery 
systems are the improvement of film forming properties and the appearance of the 
film, decreasing the glass transition temperature of the polymer, preventing film 
cracking, increasing film flexibility and obtaining desirable mechanical properties. 
In transdermal systems, plasticizers are used to improve the brittleness of the 
polymer and to provide flexibility.  Upon addition of plasticizer, flexibilities of 
polymer macromolecules or macromolecular segments increase as a result of 
loosening of tightness of intermolecular forces. 
Penetration enhancers 
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 The compounds which promote the penetration of topically applied drugs 
are commonly referred as absorption promoters, accelerants, or penetration 
enhancers. These are incorporated into a formulation to improve the diffusivity 
and solubility of drugs through the skin that would reversibly reduce the barrier 
resistance of the skin. 
Table 3 Mostly used components in TDDS 
Components Mostly Used 
Polymer matrices  Natural/Semi Synthetic Polymer 
Gelatin, Gum Arabic, Methyl cellulose, Arabino 
galactan, Starch, Shellac, Proteins, HPMC, Sodium 
CMC, Natural rubber, Zein 
 Synthetic Elastomers 
Neoprene, Polysilozane Silicone rubber, Chloroprene, 
Hydrin rubber, Acrylonitrile, Butyl rubber, Nitrile 
Rubber 
 Synthetic Polymers 
Polyethylene, Polystyrene, Acetal copolymer, 
Polyvinyl chloride, Polyester, Epoxy Polyamide 
Polyvinyl acetate, Ethylene vinyl acetate copolymer, 
Eudragits 
Semi permeable 
membrane 
Ethylene-vinyl acetate copolymer, Silicones, High density 
polyethylene, Polyester elastomers, Cellulose nitrate, 
Cellulose acetate 
Pressure sensitive 
adhesives 
Acylates  
Polyisobutylene adhesives  
Polysiloxan adhesives 
Backing laminates Polyethylene film, Polyester film, Polyolefin film, 
Aluminum vapor coated layer, Ethylene vinyl acetate, 
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Components Mostly Used 
Polypropylene, 
Polyvinylidene chloride, Polyurethane 
Release liners Polyester foil, Metalized laminate, Silicone, 
Fluorosilicone, 
Perfluorocarbon polymers 
Solvents Chloroform, Methanol, Acetone, Isopropanol, DCM 
Plasticizers Phthalate esters, Phosphate esters, Fatty acid esters, 
Glycol derivatives such as PEG 200, PEG 400 
Penetration 
enhancers 
 Lipophilic Solvents 
Dimethyl formamide, 2-Pyrrolidone, DMSO 
 Surface Active Agents 
Dimethyl formamide, 2-Pyrrolidone Sodium lauryl 
sulfate, Dodecyl methyl sulfoxide 
 Two Component Systems 
PG, Oleic acid, 1-4 Butadiol, Linoleic acid, Tweens, 
Spans 
 
Approaches to Development of TDDS (Vyas et al., 2002) 
 Several technologies have been successfully developed to provide rate 
control over the release and the transdermal permeation of drugs. There are two 
concepts in the design of TDDS namely, rate programmed systems and physical 
stimuli activated systems. 
 
Rate programmed systems 
 Drug in reservoir 
 Drug in matrix 
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 Drug in adhesive 
 Drug in micro reservoir 
Physical stimuli activated system 
 Structure based system 
 Velocity based system 
 Electrically based system 
 
Polymer Membrane Permeation Controlled TDDS 
 In this system, the drug reservoir is encapsulated in a compartment 
moulded from a drug impermeable backing layer and a rate controlling polymeric 
membrane. In the drug reservoir compartment, the drug particles are either 
dispersed in a solid polymeric matrix or suspended in an unleachable viscous 
liquid medium. On the external surface of the polymeric membrane, a thick layer 
of drug compatible adhesive polymer such as silicone or polyacrylate adhesive is 
applied to provide an intimate contact between device and skin surface. Several 
TDDS formulations have been marketed from this technology. E.g. 
 Transderm - Scop (Ciba / Alza) 
 Transderm-Nitro (Ciba /Alza) 
 Estraderm (Novartis) 
 Nicoderm (Alza) 
 Catapress-TTS (Boehringer/ Ingelheium) 
 Durogesic (Janssens) 
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Figure 1 Membrane permeation controlled TDDS 
Matrix Diffusion Controlled Systems (Monolith or Matrix Systems) 
 The drug reservoir in this type of devices is formed by homogeneously 
dispersing the drug particles in a hydrophilic or lipophilic polymer and the 
medicated polymer is then moulded into a medicated disc with a defined surface 
area and thickness. This medicated disc is then glued to a base plate, which is 
sealed to a drug impermeable backing. Most of these systems do not have an 
adhesive overlay but instead possess a peripheral adhesive ring. E.g., NTS 
(Hercom), ProStep (Parke-Davis). 
 
Figure 2 Matrix diffusion controlled TDDS 
 
Drug reservoir gradient controlled TDDS 
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 To overcome non-zero drug release profile, polymer matrix drug 
dispersion type TDDS can be modified to have the drug loading level varied in an 
incremental manner, forming a gradient of drug reservoir along the diffusional 
path across the multi laminate adhesive layer, E.g. NitroDur (Alza). 
Adhesive Diffusion-Controlled TDDS 
 In this, the drug reservoir is formulated by directly dispersing the drug in 
an adhesive polymer on a flat sheet of drug impermeable backing to form a thin 
drug reservoir layer. Layers of non-medicated rate controlling adhesive polymer 
of constant thickness are applied to produce an adhesive diffusion controlled drug 
delivery system. E.g. 
 Deponit (Wyeth / Schwartz)  
 Frandol Tape (Toaeiyo) 
 Minitran (3 M Riker) 
 Habitrol (Novartis) 
 Nicotinell (Novartis) 
 
Figure 3 Adhesive diffusion controlled TDDS 
 
Micro-reservoir / Micro sealed Controlled TDDS 
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 These systems are a combination of the reservoir and matrix dispersion 
type drug delivery systems. In these systems, drug dispersion is prepared by 
suspending the drug in an aqueous polymer solution and then the drug suspension 
is dispersed homogeneously into lipophilic polymer by high shear mechanical 
force to form microscopic spherical reservoir with the drug entrapped. This 
unstable dispersion is stabilized by cross-linking the polymer chains by the 
addition of polymeric cross-linking agents. This matrix is then attached to 
adhesive form (flexible) backings. The system has a peripheral adhesive ring, E.g., 
Nitro Disc (nitroglycerin) (Searle). 
 
Figure 4 Micro-reservoir controlled TDDS 
Skin, the Integumentary System 
Structure Of Skin (Breathnach, 1971) 
 The skin is the largest organ of human body approximately weighing 16% 
of bodys weight. The skin of an average adult body covers a surface area of 
approximately 2 m2 and receives about one-third of the blood circulating through 
the body. It is the major interface between the environment and the human organs 
and so it serves many specialised functions. It regulates body temperature to 
protect against hypothermia and hyperthermia. It protects from the invasion of 
noxious substances, UV light, heat and micro-organisms. Skin is used for the 
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delivery of drug because skin has large surface area; there is systemic access 
through underlying circulatory and lymphatic networks. 
 The skin is made up of multiple layers, epidermis, dermis and hypodermis 
and it contains appendages that include sweat glands, sebaceous glands, and hair 
follicles. 
 The superficial epidermis is a stratified epithelium largely composed of 
keratinocytes. Within the epidermis, there are several other cell populations, 
namely melanocytes, which donate pigment to the keratinocytes, Langerhans’ 
cells, which have immunological functions and Merkel cells. Stratum corneum 
forming the outermost layer of the epidermis is the rate-limiting barrier to 
percutaneous drug transport. In fact, the stratum corneum is a remarkably more 
formidable barrier to drug transport than the epithelial barriers of gastrointestinal, 
nasal, buccal, vaginal, or rectal delivery routes. 
 The inferior layer is the hypodermis, which is largely made up of adipose 
tissue and mainly functions as an insulator and cushion. Above this layer is 
dermis, which is about 2-3mm thick and consist of connective tissue, which 
adhere to the epidermis and the hypodermis. The dermis is responsible for the skin 
pliability and mechanical resistance and it’s also involved in the regulation of 
body temperature. It contains the sense organs for touch, pressure, pain and 
temperature. The dermis is considered to be the primary site of material exchange 
between the skin and blood as it has a dense network of capillaries. The is known 
as transdermal administration. 
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Figure 5 Skin and its appendages 
Drug Delivery Routes across Human Skin 
 Percutaneous absorption of drug molecules is of particular importance in 
the case of transdermal drug delivery systems because the drug has to be absorbed 
to an adequate extent and rate to achieve and maintain uniform, systemic, 
therapeutic levels throughout the duration of use. In general, once drug molecules 
cross the stratum corneal barrier, passage into deeper dermal layers and systemic 
uptake occurs relatively quickly and easily. 
 Drug molecules can penetrate through skin via three pathways: 
 Sweat ducts 
 Hair follicles 
 Sebaceous glands 
 Or directly across the stratum corneum. The human skin is a readily 
accessible surface for drug delivery as it contains 10-70 hair follicles and 200-250 
sweat ducts per cm2 of the skin. 
Principles of Transdermal Permeation (Misra, 2004) 
 Transport of hydrophilic or charged molecules is especially difficult 
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attributable to the lipid-rich nature of the stratum corneum and its low water 
content; this layer is composed of about 40% lipids, 40% protein, and only 20% 
water. Transport of lipophilic drug molecules is facilitated by their dissolution into 
intercellular lipids around the cells of the stratum corneum. Absorption of 
hydrophilic molecules into skin can occur through ‘pores’ or openings of the hair 
follicles and sebaceous glands, but the relative surface area of these openings is 
barely 1% of the total skin surface. This small surface area limits the amount of 
drug absorption. 
 The various steps involved in transport of drug from patch to systemic 
circulation are as follows: 
 Diffusion of drug from drug reservoir to the rate controlling membrane. 
 Diffusion of drug from rate limiting membrane to stratum corneum. 
 Sorption by stratum corneum and permeation through viable epidermis. 
 Uptake of drug by capillary network in the dermal papillary layer. 
 Effect on target organ 
 The rate of permeation, dq/dt, across various layers of skin tissues can be 
expressed as,  
 dq / dt = Ps ( Cd - Cr ) ---------- (1) 
 Where, Cd and Cr are the concentrations of a skin penetrant in the donor 
phase (stratum corneum) and in the receptor phase (systemic circulation) 
respectively; and Ps is the overall permeability coefficient of the skin. 
 Ps = Ks.Dss / hs --------- (2) 
 
 Where, Ks = Partition coefficient of the penetrant 
 Dss = Apparent diffusivity of penetrant 
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 hs = Thickness of skin 
 Thus, permeability coefficient (Ps) may be a constant, if Ks, Dss and hs 
terms in equation (2) are constant under a given set of conditions. A constant rate 
of drug permeation is achieved, if Cd >> Cr. 
 Then, the equation (1) may be reduced to, 
 dq / dt= Ps.Cd---------- (3) 
 The diffusional resistance encountered, limit the molecular penetration 
through the various regions of the skin. The total diffusional resistance (Rskin) to 
permeation through the skin has been described by Chien as, 
 (Rskin) = Rsc. Re. Rpd 
 Where, R is the diffusional resistance, and subscripts sc, e and pd refer to 
stratum corneum, epidermis and papillary layer of the dermis respectively. Of 
these layers the greatest resistance is put up by the stratum corneum and tends to 
be the rate-limiting step in percutaneous absorption. 
Migraines (Estemalik et al., 2013) 
 Migraines are intense headaches, sometimes causing loss of energy or 
strength. 
Types of Migraine 
 The most common types of migraine are  
Classical migraines:  
 A migraine with aura involving number of different sensations that ranges 
from visual disturbances to physical sensations. 
 
Common migraines: 
  A migraine without aura characterized by moderate to severe throbbing 
Introduction 
 
 
Department of Pharmaceutics   20 
and unilateral pain.  
 Other types of migraine include basilar artery migraine, abdominal 
migraine, hemiplegic migraine, menstrual migraine, chronic migraine and 
cluster migraine. 
The Signs of Migraine 
 The associated symptoms that can prevent an individual from continuing 
with their daily life, and these can occur with or without the headache. 
 Intense throbbing headache, often unilateral; 
 Nausea, loss of appetite and / or vomiting. May also experience diarrhoea;  
 Photophobia (excessive sensitivity to light and aversion to bright light); 
 Phonophobia (an unusual fear of sound); 
 Other common aura symptoms you may experience include: tingling or 
pins and needles in the limbs, an inability to concentrate, confusion, and 
difficulty in speaking, paralysis or loss of consciousness (in very rare 
cases). 
 These symptoms, often called ‘aura’, can occur before an attack happens 
lasting from a few minutes up to an hour. However, this is usually only 
experienced by about 20 - 30% of people.  
 The symptoms of a migraine can vary from person to person and during 
different attacks. Migraine attacks may differ in their frequency, duration and 
severity, although, normally they last between 4 and 72 hours, and most people 
are symptom-free between attacks. 
 
The Causes of Migraine 
 Disruption of normal brain functioning is believed to be the underlying 
Introduction 
 
 
Department of Pharmaceutics   21 
cause of the migraine pain and aura. The vascular theory suggests that migraines 
results from the widening of blood vessels surrounding the brain.  
 In recent years the understanding of migraine within the medical world has 
greatly improved, recognizing that migraine is a disorder that involves many 
aspects of physiology, including the CNS, neurotransmitters and other chemicals 
within the brain. Migraine is thought to be caused by a release of 
neurotransmitters (chemical messengers) through nerve endings in the trigeminal 
system located in the brain. When a migraine attack has been triggered, this is 
then thought to expand the blood vessels in the brain. 
 Recent research confirms a genetic link to migraine; people with a DNA 
variant on chromosome 8 between two genes - PGCP and MTDH / AEG-1 have 
been found to have a significantly greater risk of developing migraine. It appears 
that this DNA variant regulates the levels of glutamate – a chemical, known as a 
neurotransmitter, that transports messages between nerve cells in the brain; an 
accumulation of this chemical in the brain can cause migraine attacks. Research 
into preventing the buildup of glutamate and other causes in migraine is still 
ongoing. 
The Triggers of Migraine 
 Migraine sufferers have their own individual triggers. The most common 
migraine ‘triggers’ are: 
• Lack of food or infrequent meals (e.g. missing meals) 
• Changes in the weather (e.g. strong winds, extreme heat or cold) 
• Stress 
 
• Changing sleep patterns (e.g. weekend lie-ins or shift work), sleeping more 
 or less than usual 
• Certain medications 
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• Certain foods (including products containing caffeine, tyramine, alcohol, 
 monosodium glutamate) 
• Hormonal factors (e.g. monthly periods, the contraceptive pill, HRT or the 
menopause; migraines tend to intensify during puberty and disappear 
during menopause) 
• Overtiredness/over-exertion (both physical and mental) 
• Extreme emotions (e.g. anger, or grief) 
• Environmental factors (e.g. loud noise, bright / flickering lights, strong 
 smells, hot stuffy atmospheres, etc.) 
The Five Stages of Migraine 
 In adults a migraine attack actually comes in 4 or 5 phases- that roll on 
from each other; however not everyone has all five phases. 
1. Warning phase (known as prodrome) can occur hours or even days before 
the aura or headache begins. It is considered as an integral component of the 
migraine process. It acts as a warning sign that a migraine is imminent. 
Prodromes are characterized by mood changes, food cravings, feeling tired or 
hyperactive, or excessive yawning. Some people may also experience fatigue 
or stiffness in the neck. 
2. Aura includes a wide range of neurological symptoms – sensory disturbances, 
motor disturbances, verbal disturbances and visual disturbances. 
3. Attack phase involves head pain which can be severe and even unbearable. It 
is usually one sided, but some sufferers get the pain on both sides of the head, 
or over the forehead, but not usually at the back of head. 
 
4. Resolution (known as postdrome) may last up to 48 hrs. Most attacks slowly 
fade away, but some stop suddenly after the sufferer is sick or cries a lot. 
Sleep seems to be the best ‘cure’ for many sufferers, who find that even an hr 
or 2 can be enough to end an attack. 
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5. Recovery (hangover or run over phase): is the final stage and can takes hrs 
or even days for this hangover type feelings to disappear 
 In children the migraine attack is often shorter and it may therefore not be 
possible to fully make out the different phases. 
The Medications for Migraine 
 Although there is no miracle cure for migraine, it is possible to bring the 
condition under control using a wide range of treatments that are available. 
Effectiveness of these treatments can vary between individuals. Migraine 
treatment falls into 2 main groups: ‘acute’ and ‘preventive’ medication. Patients 
with frequent attacks usually require both. 
 Acute (abortive or rescue) therapies reverse, or at least stop, the 
progression of a headache that has started. The choice of abortive medications for 
an individual patient depends on the severity of the attacks, associated symptoms 
such as nausea and vomiting, co morbid problems and the patient’s treatment 
response. 
 Simple analgesics alone or in combination with other compounds have 
provided relief for mild to moderately severe headaches and sometimes even for 
severe headaches. Acute treatment is most effective when given within 15 minutes 
of pain onset and when pain is mild. Analgesics used in migraine include 
acetaminophen, NSAIDs and narcotic analgesics (e.g.: oxycodone, morphine 
sulfate). 
 
 For more severe pain, 5-HT 1 agonists (triptans) and / or opioid analgesics 
are used, either alone or in combination with dopamine antagonists 
(prochlorperazine). The use of abortive medications must be limited to 2-3 days a 
week to prevent development of a rebound headache phenomenon. 
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 Intravenous metoclopramide can be an effective therapy for acute 
migraine, but the optimal dosing has not been established. 
 Preventive (prophylactic) therapy given even in the absence of a headache 
aims to reduce the frequency and severity of the migraine attack, make acute 
attacks more responsive to abortive therapy, and perhaps also improve the 
patient’s quality of life. 
 Propranolol, timolol, methysergide, valproic acid and topiramate have 
been approved by the FDA for migraine prophylaxis. The 3 classes of 
prophylactic drugs include- antiepileptics, antidepressants and antihypertensives. 
 Complementary or alternative can often provide relief and / or help 
migraineurs to manage their migraine. Mindfulness based stress reduction and 
home meditation have been studied as a method to reduce the pain and improve 
health related quality of life in patients with chronic pain syndromes. 
 Biofeedback, cognitive behavioral therapy and relaxation therapy are 
frequently effective against migraine headaches and may be used adjunctively 
with pharmacologic treatments. For those with neck tension or back problems, 
acupuncture, massage and osteopathy can be of benefit. Occipital nerve 
stimulators may be helpful in patients whose headaches are refractory to other 
forms of treatment. 
Migraine - Specific Oral Medications 
 Migraine - specific oral medications include mainly 2 categories triptans 
and ergot alkaloids. The specific ergot alkaloids include ergotamine and 
dihydroergotamine. 
 The triptans share a common mechanism of action, but they differ in their 
routes of administration, onset of action and duration of action. Routes of 
administration include oral, intranasal, subcutaneous, and intramuscular. 
Transdermal patches have proved effective for the delivery of Sumatriptan, and 
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one such product has received FDA approval. 
 All the triptans are most effective when taken early during a migraine 
attack and all may be repeated in 2 hrs as needed, with a maximum of 2 doses 
daily. Triptans should not be used more than 3 days weekly, to avoid transformed 
migraine and medication overuse headache. 
 The mechanism of action for triptans has not been completely outlined, but 
there are two possibilities that have been proposed. The first recommend that 
triptans may activate serotonin (5HT1B/1D) on presynaptic trigeminal nerve 
endings to inhibit the release of vasodilating peptides. The second focuses on the 
direct vasoconstrictor actions of direct 5-HT agonists and the possible prevention 
of vasodilation that would lead to activation of nerve endings in the cerebral 
vasculature that produce pain. 
 The safety of triptans is well established, and the risk of de novo coronary 
vasospasm from triptan use is exceedingly rare. However, triptans should not be 
taken by patients with known or suspected coronary artery disease, as they may 
increase risk of myocardial ischemia, infarction, or other cardiac or 
cerebrovascular events. 
 
 
 
 
Table 4: Currently available triptan medications 
Triptan Available Dose Forms 
Alsuma ® (sumatriptan) injectable 
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Amerge® (naratriptan) Oral 
Axert® (almotriptan) Oral 
Frova® (frovatriptan) Oral 
Imitrex® (sumatriptan) Oral, injectable, intranasal 
Maxalt® (rizatriptan) Oral, also available in an orally disintegrating tablet 
Relpax® (eletriptan) Oral 
Onzetra ™ Xsail 
(sumatriptan) 
intranasal 
Sumavel® (sumatriptan) Needless injectable device 
Treximet® 
(sumatriptan/naproxen) 
Oral 
Zembrace ™ (sumatriptan) injectable 
Zomig® (zolmitriptan) Oral, also available in an orally disintegrating tablet, 
intranasal 
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RESEARCH OBJECTIVE 
 
 Almotriptan Malate is a highly selective serotonin 5-HT1B/1D receptor 
agonist. According to the FDA Clinical Review, Almotriptan Malate is effective 
in the acute treatment of moderate to severe migraine attacks in adult and 
adolescent patients with a history of migraine with or without aura. Several 
studies have reported that Almotriptan Malate has the best sustained pain-free rate 
and the lowest adverse events rate of all the triptans. It is consistently one of the 
preferred triptans in multi attribute decision-making analyses. 
 
Almotriptan Malate is administered as oral tablets (basically 12.5 mg) and 
although its absorption is good after oral administration, the mean absolute 
bioavailability is 69.1%. As mentioned, the bioavailability of Almotriptan Malate 
is somewhat limited after oral dosing. Parenteral dosing is an alternative, but it 
involves obvious inconveniences. Bearing in mind the pharmacokinetic properties 
of this agonist and its superior efficacy and tolerability profile in comparison to 
other triptans, an alternative route of Almotriptan Malate delivery, such as 
transdermal administration, could represent a new and valid pharmaceutical form. 
Furthermore, it is well known that Almotriptan Malate involves a much lower risk 
of adverse events than Sumatriptan, Zolmitriptan and Rizatriptan, making it a 
better tolerated and more cost-effective choice for triptan-naïve patients 
(Calatayud-Pascual et al., 2011). 
 Many studies conducted in vivo have demonstrated that the transdermal 
administration of triptans is possible. In view of the above facts, in the present 
investigation, an attempt was made to develop matrix type transdermal patches of 
Almotriptan Malate using suitable combination of hydrophilic polymer like 
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HPMC K 15M with hydrophobic polymers like ERS 100 and EC. These polymers 
were used due to its low toxicity, biocompatible, exhibits minimal cell adhesion, 
good chemical stability and film-forming ability. So the aim of the present 
research work is to formulate and optimize a stable and sustained release 
transdermal formulation by using various polymers in order to avoid the first-pass 
effect and to obtain great therapeutic efficacy. 
Specific objectives of investigation 
 To design the formula for transdermal patches, preliminary trials were 
 conducted with different concentration of different polymer combination. 
 To select the best polymer combination. 
 To carry out the compatibility studies of drug and selected polymer 
 combinations. 
 To incorporate selected model drug candidates in the formula and prepare 
 patches. 
 To characterize the formulated patches for the physico-mechanical 
 characteristics. 
 To carry out the in vitro drug release studies of the formulated patches 
 through dialysis membrane using Franz diffusion cell. 
 To design the optimized formulation by simple 22 factorial designs by 
 using statistical software. 
 To check the stability of the formulated patches. 
 To evaluate the drug release kinetics for the best formulation among the 
 other patches 
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PLAN OF RESEARCH WORK 
 
 Literature survey on TDDS, Almotriptan Malate, migraine and 
 antimigraine drugs 
  
 Selection of polymers 
 
 Designing the formula for preparing transdermal patches 
 
 Preformulation studies 
 
 Formulation of Almotriptan Malate loaded transdermal patches 
 
 Characterization of the formulated patches including physico mechanical 
 studies, in vitro drug release studies etc 
 
 Statistical optimization to determine the best prepared formulation 
 
 Stability studies 
 
 Drug release kinetic studies of the best formulated patches 
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  LITERATURE REVIEW 
1. Srilakshmi et al., (2017) developed matrix type transdermal therapeutic 
system containing Irbesartan, an angiotensin receptor blocker, with 
different ratios of hydrophilic and hydrophobic polymeric concentration by 
solvent evaporation technique. The prepared patch showed satisfactory 
physiochemical characteristics of weight uniformity, thickness, folding 
endurance, moisture absorption for stability of the formulation and drug 
content were uniform in all patches. In vitro study was carried out by using 
Franz diffusion cell having cellophane membrane & determined the 
amount of drug present in the formulated patch. On the basis of the in vitro 
drug release and drug content result, formulation F5 was concluded as an 
optimized formulation, which had its maximum percentage of drug 
release. 
 
2. Rahul Shivajirao Solunke et al., (2016) formulated and evaluated TDDS 
of an anti – diabetic drug, Repaglinide, using polymers such as HPMC & 
Eudragit RLPO by solvent casting technique. Repaglinide with a shorter 
half-life and low bioavailability undergoing extensive first pass 
metabolism has chosen for TDDS to maintain its therapeutic level. The 
prepared formulations were evaluated for different physicochemical 
characteristics like weight variation, folding endurance, flatness, pH of 
patches, % moisture content, % moisture uptake, % elongation, % drug 
content & % drug release. The in-vitro drug release data has shown that 
the drug release followed zero order kinetics & Higuchi model, Based on 
the result of evaluation parameters obtained from the formulation, F2 is 
considered as an optimized formulation which showed high percentage of 
drug release (98.20% at 14 hour) with diffusion mediated mechanism. 
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3. Apoorva Srivastava et al., (2016) formulated TDDS of Timolol maleate, 
an anti-hypertensive drug using various polymers such as EC, ERS100 & 
ERL100 by solvent casting method. To improve the patch performance 
and drug release permeation enhancers like Tween 80 or Span 80 were 
added whereas glycerin was used as a plasticizer. It was observed that F5 
follows the zero order as their R2 values were higher than other model. It 
was concluded that this formulation released drug in control manner and it 
is the ideal method of drug release to achieve pharmacological prolonged 
action. 
 
4. Anil kumar et al., (2016) prepared Almotriptan chewable tablets using  
3 various superdisintegrants cross povidone, cross caramellose and sodium 
starch glycolate and other ingredients in varying concentrations and were 
subjected to weight variation, drug content uniformity, lock length, 
dissolution, drug excipients interaction and short-term stability studies. 
The results of % compressibility index and hausner’s ratio for the entire 
formulation showed fair flow properties. The entire tablet passes weight 
variation test, as the average % weight variation was within the 
Pharmacopeial limit - 7.5%. The concentration of the drug in all the 
formulations with different polymers was found to be 97.35 – 99.58%. It 
was within the IP limits. The overall results indicated that formulation F6 
with cross caramellose (7.5%) had a higher edge compared to other 
formulations containing super disintegrants and palatability is good. 
 
5. Bhavani Boddeda et al., (2016) prepared and evaluated patches of 
synthetic antifungal agent, Fluconazole. Preliminary trials were conducted 
with different polymer combination (PVA: PVP, HPMC K4M: PVP, 
HPMC K15M: PVP, HPMC K100M: PVP and EC: PVP). In this F2 & F4 
were selected depending on their parameters such as tensile strength and 
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folding endurance. By using 2 different grades of HPMC and PVP 
concentrations as levels, HPMC & PVP as factors, the formulation were 
incorporated in 22 factorial designs by using DOE software. The drug 
release through the transdermal patches of Fluconazole followed first order 
kinetics with diffusion controlled mechanism. 
 
6. Sirisha Yella et al., (2016) prepared orally disintegrating tablets of 
Almotriptan and determined the effect of various diluents and super 
disintegrants in various ratios on drug release. The formulation was 
developed to increase the bioavailability of the drug using optimization 
technique and effect of various excipients has been studied to obtain an 
optimized formulation. Diluents such as microcrystalline cellulose, spray 
dried lactose, mannitol and starch were employed and super disintegrants 
such as cross povidone, cross carmellose sodium and sodium starch 
glycolate were used in different ratios. All the formulations were evaluated 
or precompression and post compression parameters, in which 
precompression studies showed statisfaction. Formulation F23 having 
diluents as mannitol and superdisintegrants as SSG (8%) showed 
maximum drug release of 100.03% within 20 min among all the other 
formulation. From the optimized formulation the drug release kinetics was 
found to follow first order kinetics. 
 
7. Shyam P. Bihade et al., (2014) focused on the development and 
evaluation of Eletriptan transdermal patches. Matrix types transdermal 
patches were prepared using HPMC K100LV / K15M grades polymers. 
The solvent used for the preparation was water. PEG 400 was used as 
plasticizer. The drug release of the optimized batch F1 was found to be 
86.43% providing sustained transdermal delivery for prolonged periods in 
the management of migraine. 
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8. Soujanya et al., (2014) developed a transdermal therapeutic system for 
Lornoxicam using various polymers like EC and HPMC and natural 
permeation enhancers like Eugenol and Cineole by solvent casting method. 
The prepared patches were evaluated for physicochemical properties,  
in vitro drug release, ex vivo skin permeation studies and in vivo studies. 
The interactions between Lornoxicam and polymers were investigated by 
FTIR. The in vitro release studies revealed that the release was sustained 
up to 24h and it followed zero order kinetics. Finally, the best formulation 
(L3) selected through in vitro study was subjected to ex vivo skin 
permeation using rat skin and in vivo studies in rabbits. The patch was also 
subjected to skin irritation and anti inflammatory activity and found that 
there was no skin irritation and edema levels were lowered in the albino 
rats. 
9. Jayesh et al., (2014) prepared and optimized Nifedipine transdermal patch 
by using D-optimal mixture design. The prepared transdermal patches 
were evaluated for various parameters like drug excipients compatibility 
study, physicochemical evaluation, mechanical properties, in vitro drug 
release and in vitro permeation study. The result of evaluation parameters 
demonstrated a successful development of transdermal patch with PVP 
and EC as rate controlling polymer. For optimization, PVP & EC content 
were selected as the independent variables whereas amount of drug 
release, cumulative amount of drug permeated at 24h, permeation flux 
were taken as dependent variable. The optimized transdermal patch was 
prepared with 90.91 % PVP and 9.09 % EC. This developed optimized 
transdermal patch showed prolonged sustained release of Nifedipine with 
high permeation rate, promising improved patient compliance and 
bioavailability. 
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10. Prabhakar et al., (2014) developed Azelnidipine transdermal patches by 
solvent casting method using different amounts and combination of HPMC 
E15, EC and ERS100 and studied the effect of DMSO on drug permeation 
across the rat abdominal skin. The prepared patches were subjected to 
physicochemical studies such as drug content, weight variation, thickness, 
moisture absorption, moisture loss, WVTR and folding endurance. The 
prepared films were smooth, flexible, uniform thickness and content of 
drug. Ex-vivo studies showed that as an increasing DMSO concentration 
increased cumulative amount of drug released. 
 
11. Karva et al., (2013) developed a quantitative estimation of Almotriptan 
Malate in pharmaceutical formulation. The stock solution of the drug was 
prepared and subsequent suitable dilution was prepared in 0.1N HCl to 
obtain standard curve. The standard curve showed 2 absorption maxima, 
one at 283.000 nm and the other at 283.00 nm. The drug obeyed Beer 
Lambert’s law in the concentration range of 10-100 µg/ml with R value 
0.9998 at 283.00 nm. Results were been validated as per ICH guidelines. 
 
12. Narayana Charyulu et al., (2013) designed and evaluated melt in mouth 
films of Almotriptan using polymers pullulan, carrageenan, xanthum gum 
and guar gum as the film forming agents, glycerol as the plasticizer, 
sorbitol as the sweetener and glycolate as the disintegrants. This 
formulation was found to have quick onset of action which can be a merit 
for managing the severe migraine attack and also aiding in enhanced 
bioavailability. The films prepared by solvent casting technique were 
evaluated for physicochemical characterization, in vitro disintegration and 
in vitro drug release studies. 
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13. Akhila Alladi et al., (2012) formulated and evaluated taste masked 
Almotriptan ODT by using 2 taste masking agents namely Eudragit EPO 
and Precirol A To5 and different superdisintegrants in different ratios. Due 
to its bitter taste formulating Almotriptan into an ODT was a challenge. 
The effect of different superdisintegrants at different concentration on in-
vitro release was studied. Almotriptan release from ODT was directly 
proportional to the concentration of the superdisintegrants used. The 
optimized formulation was found to release the drug in minimum time and 
is found to be stable. 
 
14. Michail Vikelis et al., (2012) developed the iontophoretic sumatriptan 
patch. Two trials have been performed to evaluate the pharmacokinetic 
profile of transdermal iontophoretic delivery of sumatriptan which 
indicated that the administration of sumatriptan transdermally is fast, 
consistent, and well tolerated without typical triptan-related adverse 
effects. The long-term safety and efficacy of the sumatriptan patch was 
examined in a subsequent open-label, extension study. Patch number 
containing 120 mg of Sumatriptan Succinate, was selected for further 
development under the commercial name Zelrix™. This device consists of 
a thin patch containing two shallow wells filled with chemicals that act as 
electrodes, each with nonwoven pads placed on top. They concluded that 
this could be a non-invasive process where no disruption of the skin takes 
place and the rate and amount of medication delivery is controlled by a 
microprocessor, which can be activated by the user. 
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DRUG PROFILE 
ALMOTRIPTAN MALATE 
Indications:  
 Acute treatment of migraine attacks in patients with or without aura 
Class:  
 Selective serotonin (5-HT1B/1D) receptor agonist 
Chemical name:  
 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]-methyl]-sulfonyl]-
pyrrolidine-hydroxybutanedioate(1:1) 
Molecular formula: C17H25N3O2S-C4H6O5 
Molecular mass: 469.56 g/mol 
Structural formula: 
                                    
Physical Form:  
 White to slightly yellow crystalline powder 
Solubility:  
 Freely soluble in water and methanol but practically insoluble in ethanol 
and methylene chloride. 
 pKa: 8.77 at 22 ± 2°C 
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Melting Point: 167 – 173°C 
pH: 1% solution in purified water has pH 4.1 
Partition Coefficient: 
 A partition coefficient of 0.008 between octanol and water was 
determined, when measured at the normal pH value (5.4 -6.3) for purified water. 
Dosage:  
 Recommended dose in adults and adolescents (age 12 – 17 yrs) is  
6.25mg – 12.5mg, with 12.5mg as the most effective dose in adults. If after the 
initial dose, the headache returns, another dose may be taken after 2 hours. The 
maximum daily dose should not exceed 25mg. In case of hepatic or renal 
impairment dose should be adjusted in to a starting dose of 6.25mg and a 
maximum of 12.5mg over a 24hr period. 
Dosage form: White, coated, circular, biconvex tablets 
Dosage strength: 6.25mg and 12.5mg 
Overdosage: Hypertension or any other cardiovascular symptoms can occur 
Pharmacokinetic data:  
 Absolute bioavailability: 70% 
 Protein binding: 35% 
 Mean apparent volume of distribution: 180-200 liters (approx) 
 Metabolism: Major route – MAO mediated oxidative deamination (approx 
27% of dose) & CYP450 mediated oxidation (approx 12% of dose), Minor 
route – flavin monooxygenase  
 Biological half life: 3-4hrs 
 C
 max: 49.5 – 64 mcg/L 
Pharmacology:  
 Binds to serotonin 5- HT1B/1D receptor on extra cerebral, intra cranial blood 
vessels which leads to vasoconstriction of cranial (brain) blood vessels, thus 
affecting redistribution of blood flow. Significantly it increases cerebral blood 
flow and reduces blood flow through extra cerebral cranial vessels. A single dose 
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of almotriptan has no clinically significant effect on blood pressure or heart rate in 
both young and elderly healthy volunteers. However larger doses seem to slightly 
increase blood pressure but not beyond clinical relevance. 
Contraindications: 
 Ischemic or Vasospastic Coronary Artery Disease 
 Cardiovascular Syndromes 
 Peripheral Vascular Disease 
 Uncontrolled Hypertension 
 Ergot derived medications 
 Any other 5-HT1agonists 
 Hemiplegic or Basilar Migraine 
 Hypersensitivity 
Storage: Store at room temperature between 200C - 250C (680F – 770F) 
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POLYMER PROFILE 
HYDROXY PROPYL METHYL CELLULOSE (Wade et al., 1994) 
Nonproprietary names:  
 Hypromellose (BNF), Methyl hydroxyl propyl cellulosum (Ph Eur)  
Synonyms: 
 Cellulose hydroxyl propyl methyl ether  
 Metolose  
 Methylcellulose propylene glycol ether  
 Methyl hydroxypropyl cellulose 
 Methocel 
IUPAC name:  
 (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-
[(2R,3R,4S,5R,6R)-3,4,5- trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane 
Chemical structure: 
                             
Molecular formula: C56H108O30 
Molecular weight: 1261.45 g/mol 
Description:  
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 HPMC absorbs moisture from the atmosphere. The Ph.Eur 1992 describes 
HPMC as a partly O methylated and O-(2-hydroxypropylated) cellulose. It is 
available in several grades which vary in viscosity and extent of subscription. 
HPMC defined in the USP XXII specifies the substitution type by appending a 
four digit number to the non proprietary name, e.g. HPMC1828 .the first two 
digits refer to the approximate percentage content of the methoxy group & the 
second digits refer to the approximate percentage content of the hydroxyl propyl 
group calculated on a dried basis. 
Appearance: 
 White to creamy- white fibrous or granular powder 
Odor:  
 Odorless and tasteless 
Melting point:  
 Browning temperature 190–200°C; charring temperature 225–230°C. 
Acidity / alkalinity:  
 pH= 5.5–8.0 (1% w/v aqueous solution) 
Nominal viscosity: 15000 mPa s 
Density : 0.25-0.70 g/cm3  
Solubility:  
 Soluble in cold water forming a viscous colloidal solution, a mixture of 
ethanol & DCM, a mixture of water and alcohol and a mixture of methanol and 
DCM and practically insoluble in ethanol (95%), chloroform and ether. 
Different grades:  
 HPMC K4M, HPMC K15M, HPMC K100 
Storage:  
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 HPMC powder should be stored in well closed container, in a cool, dry, 
place. 
Functional category: 
 Coating agent 
 Film-former 
 Rate controlling polymer for sustained release 
 Stabilizing agent 
 Suspending agent 
 Tablet binder 
 Viscosity increasing agent 
Applications in pharmaceutical formulations and technology: 
  HPMC is widely used in oral and topical pharmaceutical formulations. In 
oral products, HPMC is primarily used as tablet binder, in film coating and as an 
extended release tablet matrix. Depending upon the viscosity grades, 
concentration between 2 -10%w/w are used as film forming solutions to film coat 
tablets. Lower viscosity grades are used in aqueous film coating solution while 
higher viscosity grades are used with organic solvents. HPMC is also used as 
suspending agent and thickening agent in topical formulations especially in 
ophthalmic preparations. Compared with MC, HPMC produces solutions of 
greater clarity, with fewer undispersed fibers present, and is therefore preferred in 
formulation for ophthalmic use. Concentration of between 0.45%-1.0% w/w may 
be added as a thickening agent to vehicles for eye drops and artificial tear 
solution. HPMC is also used as an emulsifier, suspending agent and stabilizing 
agent in topical gels and ointments. In addition, HPMC is used as adhesive in 
plastic bandages and as a wetting agent for hard contact lenses. It is also widely 
used in cosmetics and food products. 
 
EUDRAGIT RS 100 (Abhijit Sonje et al., 2013) 
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Nonproprietary names:  
 Methacrylic acid copolymer, polymeric methacrylates  
Synonyms:  
 Trimethyl ammonium ethyl methacrylate chloride 
 Methyl methacrylate 
 Ethyl acrylate polymer 
IUPAC name:  
 Ethyl prop-2-enoate; methyl 2-methylprop-2-enoate; trimethyl-[2-(2-
methylprop-2-enoyloxy)ethyl]azanium; chloride 
Chemical structure: 
                   
R1 = H, CH3 
R2 = CH3, C2H5 
Molecular formula: C19H34ClNO6 
Molecular weight: 407.932 g/mol 
Description: 
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 It is a 5% trimethylammoniummethacrylate chloride and is copolymers of 
acrylic and methacrylic acid esters containing some quaternary ammonium 
groups. The ammonium groups are present as salts and make the polymers 
permeable. 
Appearance:  
 Colorless, clear to cloudy granules 
Odor:  
 Slight amine like odor 
Viscosity:  
 5-15 cps 
Density: 
  0.825 g/ml 
Solubility:  
 Soluble in acetone, ethanol, methanol, propanol, DCM, ethyl acetate 
whereas practically insoluble in ether, 1 N sodium hydroxide and water. 
Storage:  
 Protect from warm temperatures and from moisture. They tend to form 
lumps at warm temperatures, but this has no influence on the quality. The lumps 
are easily broken up again. 
 
Functional category: 
 Film former 
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 Tablet binder 
 Tablet diluents 
 Suspending agent 
 Film former 
 Emulsifying agent 
 Emulsion stabilizer 
 Stabilizing agent 
Applications in pharmaceutical formulations and technology: 
 Eudragit exhibits favourable behaviour, such as no toxicity, positive 
charge and controlled release profile this makes them suitable for ophthalmic 
applications. Eudragit provide good drug release barrier with good adhesive 
strength or buccal and sublingual drug delivery. Sustained intestine drug 
deliveries was developed that could bypass the stomach and release the loaded 
drug for longer periods into the intestine by coating of Eudragit polymer. ERS 100 
vaginal suppositories containing sildenafil and other excipients give adequate 
release. Anti sense oligodeoxynucleotides were successfully delivered by 
nanoparticles prepared by ERL 100 and ERS 100. 
 
 
 
 
 
ETHYL CELLULOSE 
Nonproprietary names: Ethyl-cellulose, Ethocel  
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Synonyms: 
 Aquacoat 
 Aqualon 
 E462 
 Ethocel 
 Surelease 
IUPAC name: 
  2-[4, 5-diethoxy-2-(ethoxymethyl)-6-methoxyoxan-3-yl]oxy-6-
(hydroxymethyl) -5-methoxyoxane-3,4-diol 
Chemical structure: 
                       
Molecular formula: C20H38O11 
Molecular weight: 454.513 g/mol 
Description:  
 Ethyl cellulose is a hydrophobic ethyl ether of cellulose. It is a derivative 
of cellulose in which some of the hydroxyl groups on the repeating glucose units 
are converted into ethyl ether groups. 
Appearance: free-flowing white to tan powder 
Odor: Odorless and tasteless powder 
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Melting point: 160-210°C 
Viscosity: 18.00 – 24.00 cp 
Density: 1.07-1.18 g/cm3  
Solubility:  
 Practically insoluble in water, in glycerol and in propane-1, 2-diol but 
soluble in varying proportions in certain organic solvents depending upon the 
ethoxyl content. Ethyl cellulose containing 46 - 48% or more of ethoxyl groups is 
freely soluble in chloroform, in methanol, in toluene and in ethyl acetate. Freely 
soluble in mixture of aromatic hydrocarbons with alcohol. 
Storage:  
 Stored between 700C-30°C in a dry area away from all sources of heat and 
away from bright light. Store in a well closed container. 
Functional category 
 Coating agent 
 Flavouring  
 Tablet binder and filler 
 Film former 
 Rate controlling polymer for sustained release 
 Stabilizing agent 
 Suspending agent 
 Viscosity increasing agent 
Applications in pharmaceutical formulations and technology: 
 Ethyl cellulose is a non-toxic, stable, compressible, inert, hydrophobic 
polymer that has been widely used to prepare pharmaceutical dosage forms. It is a 
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stabilizer and thickener for foods. It is currently used in pharmaceutical 
applications for micro encapsulation of actives, controlled-release matrix systems, 
taste masking, solvent and extrusion granulation, tablet binding, and as a 
controlled-release coating for tablets and beads. It is directly extracted from plant 
fiber and is then chemically modified. It is a kind of cellulose ether and it shows 
good thermo stability and electric properties. The film made from EC has quite 
good permeability; it has been used widely as industrial air filter. 
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PLASTICIZER PROFILE 
 
POLYETHYLENE GLYCOL 
Non proprietary name: 
 Macrogol 300 
 Macrogol 1540 
 Macrogol 4000  
Synonym: 
 PEG 
 Macrogol 
 Polyoxyethylene glycol 
 
IUPAC name: α-Hydro-ω-hydroxypoly-(oxy-1, 2-ethanediyl) 
Chemical structure: 
 
 
Structural formula: 
 HOCH2(CH2OCH2)nCH2OH, where n=average number of oxyethylene 
groups. In PEG 400 n is in the range 8-10 
Molecular weight: 380-420 g/mol 
Description: Clear, colorless or slightly yellowish, viscous liquids. The odor is 
slight but characteristics, and the taste is bitter and slightly burning. 
Viscosity: 6.8-8.0 
Density: 1.13 g/cm3 
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Solubility:  
 Soluble in water, alcohol, glycol, glycerol, acetone and benzene. 
Storage:  
 Stored in well closed container. Storage under nitrogen will reduce the 
possibility of oxidation. 
 
Functional category: 
 Suppository base 
 Solvent 
 Tablet lubricant 
 Capsule lubricant 
 Ointment base 
 Pharmaceutical aid 
Applications in pharmaceutical formulations and technology: 
 It is a low molecular weight grade of polyethylene glycol. It is widely used 
as plasticizers in conjunction with film forming polymers. Their presence in film 
tends to increase their water permeability, and may reduce protection against low 
pH in enteric coating films. PEGs are useful as plasticizers in micro-encapsulated 
products to avoid rupture of the coating film when microcapsules are compressed 
into tablets. They are used as water miscible vehicles for the contents of soft 
gelatin capsules. However, they may cause hardening of the shell by preferential 
absorption of moisture from the gelatin shells. In concentration up to 30% they 
have been used as vehicles in parenteral dosage forms. The aqueous solubility or 
dissolution characteristics of poorly soluble compounds can be enhanced by 
making solid dispersions with an appropriate PEG. In aqueous vehicles, PEGs can 
be used to adjust viscosity and consistency. When used in conjunction with other 
emulsifiers, PEGs can act as emulsion stabilizers. As suppository bases, PEGs 
offer many advantages over fats, such as physical stability or better storage, high 
melting point thus withstanding exposure to warmer climates and are readily 
miscible with rectal fluids. 
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DIBUTYL PHTHALATE 
Synonyms: 
 Di-n-butyl phthalate 
 1, 2-benzenedicarboxylic acid 
 Phthalic acid di-n-butyl ester 
 1, 2-benzene dicarboxylate 
 n-butyl phthalate 
 Palatinol C 
 Butyl phthalate 
 DBP 
 DBP (ester) 
 Phthalic acid 
 Dibutyl ester 
IUPAC name: Dibutyl benzene-1,2-dicarboxylate 
Chemical structure: 
                                  
Molecular formula: C16H22O4 
Molecular weight: 278.34 g/ mol 
Description: Colorless to faint yellow oily liquid with a slight aromatic odor 
Melting point: -350C 
Boiling point: 3400C  
Partition coefficient: log P 4.72 
Relative density: 1.045 g/cm3 at 200C 
Solubility: 
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 It is almost insoluble in water but miscible with most common organic 
solvents. Very soluble in alcohol, ether, acetone & benzene. 
Storage:  
 Stored in a tightly closed container in a cool dry well-ventilated place. 
Optimum storage temperature is between 20C-80C. 
 
Functional category:  
 Plasticizer 
 Anti foaming agent 
 Ectoparasiticide 
 Additives or adhesives or printing inks 
 Putative endocrine disruptor 
 Gelling aid 
Applications in pharmaceutical formulations and technology: 
 The primary use of DBP is as a plasticizer in polyvinyl acetate emulsions. 
It is used in combination with other plasticizers in PVC applications to increase 
flexibility and workability. It is also found in fiberglass and rubbers. DBP is 
further used as plasticizers in adhesives, paints, lacquers and grouts. It is also used 
as a solvent in a number of other miscellaneous application and as a medium for 
reactions in a number of chemical processes for the manufacture of other 
substances. It is also used as an additive to adhesives or printing inks. DBP is used 
as an ectoparasiticide & also a putative endocrine disruptor. It is found in soil, air, 
water, plants and animals. DBP can also be used as a gelling aid, as a solvent, as 
an antifoam agent or as a lubricant. Its properties as lubricant are used in 
particular in textile manufacturing. DBP is also used in the coatings industry as a 
primary plasticizer solvent for nitrocellulose lacqers. 
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MATERIALS AND EQUIPMEMTS 
Table 5 List of materials used 
Materials Source 
Almotriptan Malate Azakem Laboratories, Hyderabad 
HPMC K 15M Yarrow Chem Products, Mumbai 
ERS 100 Yarrow Chem Products, Mumbai 
EC Hi Media Laboratories Pvt. Ltd, Mumbai 
PEG 400 Hi Media Laboratories Pvt. Ltd, Mumbai 
DBP SDFCL, Mumbai 
DCM Qualigens Fine Chemicals, Mumbai 
Methanol SDFCL, Mumbai 
Glycerin PAXMY Speciality Chemicals, Chennai 
 
Table 6 List of equipments used 
Equipments Model / Company 
Circular moulds Borosil Glass Works LTD. 
Digital balance Sri Mahalakshmi Scientific Co., Coimbatore 
Digital micrometer Aerospace 
Franz diffusion cell Self – fabricated 
FT – IR spectrophotometer Jasco FTIR 4100 
Heating mantle Guna Enterprises, Chennai 
Hot air oven Inlab Equipment (Madras) Pvt. Ltd. 
Magnetic stirrer Remi Motors 
pH meter Systronics, Ahmadabad  
UV - Visible spectrophotometer Jasco v 530 
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EXPERIMENTAL METHODS 
PREFORMULATION STUDIES 
 The aim of preformulation study is to generic information useful to the 
formulator in developing stable and bioavailable dosage form. The use of 
preformulation parameter maximizes the chances in formulation for an acceptable, 
safe, efficacious and stable product and at the same time provides the basis for 
optimization of the drug product quality. 
Solubility Profile of Almotriptan Malate 
 The solubility of Almotriptan Malate was tested in various solvents. A 
definite quantity (10mg) of drug was dissolved in 10ml of each solvent at room 
temperature. The solubility was observed by visual inspection. 
Development of Calibration Curve of Almotriptan Malate 
Preparation of pH 6.5 Phosphate Buffer (IP 2007 Vol 1) 
 Dissolved 60.5g of disodium hydrogen phosphate and 46g of potassium 
dihydrogen phosphate in water; 100ml of 0.02M disodium edetate and 20mg of 
mercuric chloride was added and  was diluted with water to produce 1000ml. 
Calibration Curve of Almotriptan Malate 
 100mg of Almotriptan Malate was accurately weighed into 100ml 
volumetric flask and dissolved in methanol. The volume was made up to 100ml 
with pH 6.5 phosphate buffer solution to get a concentration of 1000µg/ml. From 
this 10ml was withdrawn and diluted to 100ml with pH 6.5 phosphate buffer 
solution to get a concentration of 100µg /ml. From this standard stock solution 
0.2ml, 0.4ml, 0.5ml, 0.8ml and 1ml were withdrawn and volume was made up to 
using pH 6.5 phosphate buffer solution to get a concentration of 2, 4, 6, 8 and 
10µg/ml. Absorbance of these solutions were measured against blank of pH 6.5 
phosphate buffer solution at 227nm. 
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Compatibility Studies of Drug & Excipients (Sagar S.Jadhav et al., 2013) 
 The FTIR studies were carried out by KBr disc pellet method. 10mg of the 
samples and 400mg of KBr were taken in a mortar and triturated. A small amount 
of the triturated sample was taken into the pellet marker. It was compressed at 
10kg /cm² using a hydraulic press. The pellet was taken on the sample holder. It 
was then scanned from 4000cm-1 to 400cm-1 in FTIR spectrophotometer. Samples 
were prepared for drug and excipients also. The spectra obtained were compared 
and interrupted for functional group peaks. 
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FORMULATION OF ALMOTRIPTAN MALATE LOADED 
TRANSDERMAL PATCHES (Prabhakar et al., 2014) 
 In the present study, matrix-type transdermal patches of Almotriptan 
Malate for its low (6.25mg) and high dose (12.5mg) were prepared by solvent 
evaporation technique. A glass mould of diameter 9.6cm having surface area 
72.34cm2 were used for casting the patches. The total amount of drug to be loaded 
in the patch was calculated by measuring the total area of the petri dish in which 
the patch will be casted. 
Almotriptan Malate Loaded HPMC K 15M - ERS 100 Transdermal Patches 
 Polymeric solutions of HPMC K 15M and ERS 100 were prepared using 
DCM and methanol in 1:1 ratio (20ml) and specified amount of Almotriptan 
Malate and DBP were added and stirred well in a magnetic stirrer for 30min to get 
a homogenous solution. 5 ml of the casting solution was poured into glass a mould 
which was lubricated with glycerin; entrapped air bubbles were removed and 
dried at room temperature for 24hours for solvent evaporation. The rate of solvent 
evaporation was controlled by inverting a glass funnel over the petriplate. After 
24hours the patches were removed by peeling and cut into circle of radius 2.1cm 
having surface area 13.85cm2. These patches were kept in desiccator for 2 days 
for further drying and wrapped in aluminium foil, packed in self-sealing covers. 
Same procedure was followed for preparing transdermal patches of high dose of 
Almotriptan Malate. 
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Table 7 Composition of formulations A1 & A2 
Ingredient 
 
Quantity 
Formulation 
A1 
Formulation 
A2 
Drug Almotriptan Malate 6.25 mg 12.5 mg 
Polymers HPMC K 15 M 400 mg 400 mg 
ERS 100 600 mg 600 mg 
Plasticizer DBP 0.8 ml 0.8 ml 
Solvent DCM 10 ml 10 ml 
Methanol 10 ml 10 ml 
 
Drug Loaded HPMC K 15M – EC Transdermal Patches 
 Matrix patches containing Almotriptan Malate were prepared by 
dissolving polymers HPMC K15M and EC in suitable solvents namely DCM and 
methanol. PEG 400 is used as plasticizer. The beakers were kept on the magnetic 
stirrers for continuous stirring to get a homogenous solution. The solution was 
poured into a petri plate which was lubricated with glycerin and covered with a 
funnel in inverted position. The solvent was allowed to evaporate at ambient 
conditions for 24hours. After 24hours the patches were removed by peeling and 
cut into circle of radius 2.1cm having surface area 13.85cm2. These patches were 
kept in desiccator for 2 days for further drying and wrapped in aluminium foil, 
packed in self-sealing covers. High dose of Almotriptan Malate were also 
prepared. 
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Table 8 Composition of formulations B1 & B2 
Ingredient 
 
Quantity 
Formulation B1 Formulation B2 
Drug Almotriptan Malate 6.25 mg 12.5 mg 
Polymers HPMC K 15M 150 mg 150 mg 
EC 150 mg 150 mg 
Plasticizer PEG 400 0.5 ml 0.5 ml 
Solvent DCM 10 ml 10 ml 
Methanol 10 ml 10 ml 
Drug Loaded HPMC K 15M Transdermal Patches 
 The transdermal patches of Almotriptan Malate were prepared using 
HPMC K15M polymer by solvent evaporation method. 250mg of HPMC K15M 
polymer was weighed accurately and kept aside. The specified amount of the drug 
was weighed accurately and is dissolved in 20ml of distilled water. The beakers 
were kept for continuous stirring at room temperature. While stirring the polymer 
is added into the beaker slowly. As the drug & polymer both are hydrophilic in 
nature they get completely dissolved in solvent. PEG 400 is added to the solution. 
The whole solution was mixed thoroughly with the help of a magnetic stirrer for 
30minutes.  An inverted funnel was placed over the plate to avoid sudden 
evaporation. Then the petri plates were kept for 12 hours in hot air oven at 40o C 
for drying & the dried patches were taken out, cut to a circle of radius 2.1 cm 
having surface area 13.85 cm2 and preserved in aluminum foil for further studies. 
Same composition was used for the other dose of the drug. 
Table 9 Composition of formulations C1 & C2 
Ingredient Quantity 
Formulation C1 
 
Formulation C2 
Drug Almotriptan Malate 6.25 mg 12.5 mg 
Polymers HPMC K 15M 250 mg 250 mg 
Plasticizer PEG 400 1 ml 1 ml 
Solvent Water 20 ml 20 ml 
CHARACTERIZATION OF ALMOTRIPTAN MALATE LOADED 
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TRANSDERMAL PATCHES (Ashok et al., 2010) 
Physical Appearance 
 All the prepared patches were visually inspected for colour, clarity, 
flexibility and smoothness. 
Thickness 
 The thicknesses of the drug loaded patches were measured at 3 different 
points by using a digital micrometer and the mean value was calculated. 
Folding Endurance 
 The folding endurance was measured manually for the prepared patches.  
The prepared drug loaded patches were folded until it breaks or it develops cracks.  
Drug Content 
 An area of the films was cut and was dissolved in sufficient quantity of 
methanol. The solvent is selected in which the drug is freely soluble. The medium 
was stirred with a Teflon coated magnetic bead at 500rpm for 24 hrs. The solution 
was filtered through a Whatmann filter paper. After filtration, the absorbance of 
the diluted solution was measured spectrophotometrically with proper dilution at 
wavelength of 227nm against the reference solution consisting of placebo films 
(contains no drug) and the drug content in the film was calculated.  
 
Weight Uniformity 
 The prepared patches are dried at 60°C for 4hrs before testing. Weight 
variation is studied by individually weighing 5 randomly selected patches from 
each formulation and calculating the average weight. The weights were taken in 
an electronic digital balance. The individual weight should not deviate 
significantly from the average weight. 
 
Surface pH 
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 Surface pH of the patch was determined by allowing them to swell in 
closed petridish at room temperature for 1hr in 0.5 ml of double distilled water. 
The surface pH was then noted by bringing a combined glass electrode near the 
surface of the patch and allowing it to equilibrate for 1 minute.  
 
Swellability 
 The patches of specific area was weighed and put in a petridish containing 
10 ml of double distilled water and were allowed to imbibe. Increase in weight of 
the patch was determined at preset time intervals, until a constant weight was 
observed. 
 The degree of swelling (S) was calculated using the formula: 
 
S (%) = 100
 Wo
 Wo-Wt X  
Where S is the percent swelling 
Wt is the weight of patch at time t 
Wo is the weight of patch at time zero 
 
Percentage Moisture Absorption 
 The films were weighed accurately and kept in a desiccator containing 
anhydrous calcium chloride.  After 3 days, the films were taken out and 
reweighed. The study was performed at room temperature. 
 
The moisture uptake/ absorption was calculated using the formula: 
Percentage moisture uptake = 100
 weightInitial
 weightInitial - weight Final X  
Percentage Moisture Loss 
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 The films were weighed accurately and placed in the desiccator containing 
100ml of saturated solution of potassium chloride, which maintains 80-90% RH. 
After 3 days, the films were taken out and reweighed. The study was performed at 
room temperature. 
 
 The moisture content/ loss was calculated using the formula: 
 
Percentage moisture content = 100
 weightFinal
 weightFinal - weight Initial X   
 
Water Vapour Transmission Rate 
 Glass vials of equal diameter were used as transmission cells. These 
transmission cells were washed thoroughly and dried to a constant weight in an 
oven. About 1 g of fused calcium chloride as a desiccant was taken in the vials 
and the polymeric patches were fixed over the brim with the help of an adhesive 
tape like silicon adhesive grease and the adhesive was allowed to set for 5 
minutes. Then, the vials are accurately weighed. These preweighed vials were 
stored in a desiccator containing saturated solution of potassium chloride to 
maintain 84% RH. The vials are again weighed at the end of every 1st day, 2nd 
day, 3rd day up to 7 consecutive days and an increase in weight was considered as 
a quantitative measure of moisture transmitted through the patch. 
 The rate of water vapor transmitted was calculated using following 
formula: 
WVTR = (Wf - WI) / (A × T) × 100 
Where Wf is the final weight 
WI is the initial weight 
A is the area of film exposed (cm2) 
T is the exposure time 
In-Vitro Drug Release Study 
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 In-vitro permeation studies were performed through dialysis membrane-50 
(Hi Media) by using self fabricated Franz diffusion cell apparatus with a cross 
sectional area of 13.84 cm2. The Franz Diffusion cells used generally consists of 
donor (for placing drug or formulation) and receptor (for collecting drug samples) 
compartment. The diffusion cell consists of a sampling port and temperature 
maintaining jacket. The receptor compartment was filled with phosphate buffer 
pH 7.4 and it was stirred magnetically by placing small magnetic bead. The 
synthetic cellophane membrane was mounted between donor and receptor 
compartment of the diffusion cell. 
 The formulated patches were cut into size of 2.1 cm radius and placed over 
the drug release membrane in such a way that the drug releasing surfaces face 
towards the receptor compartment. The donor cell was fixed using clips. The 
whole assembly was fixed on a magnetic stirrer and the solution in the receptor 
compartment was constantly and continuously stirred using magnetic beads at 50 
rpm and was maintained at 37 ± 0.5° C by circulating the constant temperature 
water through outer jacket of the diffusion cells. 
 One ml of receptor solution was withdrawn at different time intervals over 
12hours. The  receptor  phase  was  replenished  with  an  equal  volume  of  
phosphate  buffer pH 7.4 at  each  sample  withdrawal . The  samples  were  
analyzed  spectrophotometrically  at  227  nm  taking  phosphate  buffer  pH  7.4  
as  blank. The cumulative percentage of drug permeated per square centimeter of 
patches at various time intervals were calculated and were plotted against time. 
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Figure 6 Franz diffusion cell 
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EXPERIMENTAL STATISTICAL DESIGN (Deore Et Al., 2013) 
 Minitab 18 trial version was used for the effect of analysis of each variable 
on the designated response. Surface plots were made for the analysis of each 
response coefficient for its statistical significance. The significant polynomial 
equations were used to validate the statistical design.  
 From the above formulations prepared the best one was selected after their 
characterization and were subjected for experimental design & data analysis. In 
this design, 2 independent factors were evaluated, each at 2 levels and according 
to a 22 factorial design and considering these two variables, 4 runs had been 
performed for both low and high doses of Almotriptan Malate. The different 
concentration of the polymers HPMC K 15M and ERS 100 were chosen as 
independent variables. Drug content, moisture absorption, moisture loss and 
cumulative % drug release at 12 hr were taken as dependent variables. 
The effect of mixture component on dependent variables were modeled using the 
following equation ܻ = 𝑏0 + 𝑏1ܺ1 + 𝑏2ܺ2 + 𝑏12ܺ1ܺ2 + 𝑏11ܺ12 + 𝑏22ܺ22 
Where Y is predicated response, 
b0 is the arithmetic mean of all responses, 
b1 & b2 are the estimated coefficient for factors A & B respectively. 
Table 10 Independent factors selected for statistical optimization 
Independent 
Factors 
Levels 
(-) (+) 
HPMC K 15M (A) 400 mg 600 mg 
ERS 100 (B) 400 mg 600 mg 
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EFFECT ON AGING 
 The effect of aging on physical appearance is studied by packing the best 
polymeric films in properly sealed aluminium foil and then storing them in a 
desiccator at 40±0.5°c and 75±5% RH for 60 days. The patches were then 
characterized for drug content and drug release study at regular intervals (0, 30 
and 60 days).  
IN-VITRO DRUG RELEASE KINETIC STUDY 
 Drug release rate kinetics of Almotriptan Malate loaded transdermal 
patches was calculated by using a software, Microsoft Office Excel Add - In. The 
in-vitro drug permeation data obtained of optimized formulation was fitted to zero 
order kinetics (cumulative amount of drug released versus time), first order 
kinetics (log cumulative percentage of drug remaining vs. time), Higuchi model 
(cumulative percentage drug release versus square root of time), Korsmeyer-
pappas model (log cumulative percentage drug release versus log time) to assess 
the kinetic modeling of drug release and the model with the higher correlation 
coefficient (i.e. higher R2) was considered to be the best fit model  
(Allena et al.,2012). 
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RESULTS & DISCUSSIONS 
PREFORMULATION STUDIES 
Solubility Profile of Almotriptan Malate 
 Solubility studies were carried out to select a suitable solvent to dissolve 
the drug and to select the dissolution medium. 
Table 11: Solubility studies 
Solvent Solubility 
Water Soluble 
Phosphate buffer pH 6.5 Soluble 
Dichloromethane Soluble 
Methanol Soluble 
 
Development of Calibration Curve of Almotriptan Malate 
Calibration Curve of Almotriptan Malate 
 In the validation studies, it was found that the estimation of Almotriptan 
Malate by spectrophotometric method at 227 nm has good reproducibility, at the 
concentration between 2-10 µg/ml. Correlation between concentration and 
absorbance was found to be 0.999845 which is closer to 1.  
Table 12 Calibration curve of Almotriptan Malate 
Concentration (µg/ml) Absorbance 
0 0 
2 0.2166 
4 0.4085 
6 0.6155 
8 0.8098 
10 1.0031 
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Graph 1 Calibration curve of Almotriptan Malate 
 
 
Compatibility Studies of Drug & Excipients 
 In the present study, physical mixture of Almotriptan Malate in solid form 
along with different polymers were prepared and analyzed by FTIR to find out the 
compatibility between the drug and polymers. The IR spectra of Almotriptan 
Malate along with the physical mixture of Almotriptan Malate with different 
polymers are shown from the graph 2-5, which showed that the drug and 
excipients are chemically compatible, as there were no abnormal peaks. 
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Table 13 FTIR interpretation of Almotriptan Maleate 
FTIR Interpretation of Drug Almotriptan Maleate 
Samples Functional group 
Type of 
vibration 
Characteristic 
absorption 
(cm-1) 
Test 
absorption 
(cm-1) 
Almotriptan 
Malate 
CH Stretching 2840-3000 2976.59 Bending 1350-1480 1433.82 
NH stretching 3400-3500 3429.78 
C=C  1400-1600 1433.82 
S=O  1030-1060 1038.45 
COOH OH  2500-3300 2563.21 C-O  1210-1320 1229.12 
 
Graph 2 FTIR of Almotriptan Malate
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Graph 3 FTIR of Almotriptan loaded HPMC K15M - ERS 100 patches 
 
Graph 4 FTIR of Almotriptan loaded HPMC K 15M - EC patches 
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Graph 5 FTIR of Almotriptan loaded HPMC K 15M patches 
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Table 14 Comparison of FTIR data of drug and polymers in samples 
Formulation 
components 
Functional 
group 
C
ha
ra
ct
er
ist
ic
 
a
bs
o
rp
tio
n(
cm
-
1 ) 
Pa
tc
h 
1(H
PM
C
 K
 
15
M
-
ER
S 
10
0) 
Pa
tc
h 
2(H
PM
C
 K
 
15
M
-
EC
) 
Pa
tc
h 
3(H
PM
C
 K
 
15
M
) 
Almotriptan 
Malate 
CH Stretching 2840-3000 2954.41 2936.98 2782.36 
CH Bending 1350-1480 1728.87 1322.98 1322.93 
NH Stretching 3400-3500 3428.66 3499.45 3325.64 
C=C 1400-1600 1728.87 1586.67 1690.3 
HPMC K 15M 
OH stretching 3700-3584 3305.39 3566.34 3325.64 
C-H stretching 
of alkyl group 2840-2960 2954.41 2855.50 2632.36 
C-H scissoring 2695-2830 2633.32 2732.56 2632.36 
ERS 100 
OH stretching 
of COOH 
group 
2500-3300 3305.39 - - 
C-H stretching 
of alkane 2890 2954.51 - - 
C=O stretching 
of carbonyl 
group 
1540-1870 1728.87 - - 
EC 
O-H stretching 3200-3600 - 3325.64 - 
C-H 2700-3800 - 2632.36 - 
C-O-C stretch 1085-1150 - 1159.01 - 
C=C 1610-1660 - 1690.3 - 
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FORMULATION OF ALMOTRIPTAN LOADED TRANSDERMAL 
PATCHES 
Calculation of total drug loading (John et al., 2014) 
 The formulation of the patch was made in such a way that each small 
circular patch of 2.1cm radius (which is the radius of the Franz diffusion cell) 
contains desired amount of the drug. The total amount of drug to be loaded in the 
patch was calculated by measuring the total area of the petri dish in which the 
patch will be casted. The calculation was done as follows; 
Total amount of drug to be loaded = (area of the petri dish in which the patch is 
moulded / area of small circular patch)   desired drug amount 
Table 15 Calculation of total amount of drug to be loaded 
Desired drug content 6.25 mg 12.5 mg 
Area of the small 
circular patch (which is 
the area of Franz 
diffusion cell) 
 
 
 
13.8474cm 2 
 
 
13.8474cm 2 
Area of the petri dish in 
which the patch is 
moulded 
 
 
72.3456 cm2 
 
 
72.3456 cm2 
 
Total amount of drug to 
be loaded 
 
(72.3456 / 13.8474) 
× 6.25 = 32.65mg 
(72.3456 / 13.8474) × 
12.5 = 65.31mg 
 
 Hence 32.65 mg and 65.31 mg of the drug were added in each formulation 
in order to get 6.25 mg and 12.5 mg per small circular patch respectively. 
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Figure 7 Prepared formulation A1  Figure 8 Prepared formulation A2 
  
Figure 9 Prepared formulation B1             Figure 10 Prepared formulation B2 
  
Figure 11 Prepared formulation C1           Figure 12 Prepared formulation C2 
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CHARACTERIZATION OF ALMOTRIPTAN LOADED TRANSDERMAL 
PATCHES 
 Transdermal patches of Almotriptan Malate were successfully prepared by 
solvent casting technique using HPMC K 15M as the hydrophilic polymer, ERS 
100 and EC as the hydrophobic polymer and DBP & PEG 400 as plasticizer. All 
the prepared formulations were evaluated for physicochemical characteristics, in-
vitro drug release studies and in-vitro drug release kinetic studies. 
Physical Appearance 
 Physical appearances of the films were evaluated. All the films were easily 
removable from the mould without any recrystallization. All the systems were 
thin, flexible, smooth and without the entrapment of air but formulation having 
only the polymer HPMC K 15M were found to be clear and transparent. The 
method adopted for casting the systems was found satisfactory. 
Table 16 Physical characters of formulated transdermal patches 
Formulation Formulation 
code 
Evaluation Parameters 
Colour Flexibility Smoothness Stickiness 
Almotriptan 
loaded 
HPMC – 
ERS100 
patches 
F A1 White Flexible Smooth Non - 
sticky 
F A2 White Flexible Smooth Non - 
sticky 
Almotriptan 
loaded 
HPMC – EC 
patches 
F B1 White Flexible Smooth Non - 
sticky 
F B2 White Flexible Smooth Non - 
sticky 
Almotriptan 
loaded 
HPMC 
patches 
F C1 Clear & transparent Flexible Smooth Sticky 
F C2 Clear & transparent Flexible Smooth Sticky 
Thickness 
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 Thickness of each film of all formulation was found to be uniform. 
Thickness ranged from 0.103 mm to 0.332 mm. 
Folding Endurance 
 Folding endurance test results indicated that the patches did not show any 
cracks even after folding 300 times and thus showing good elasticity, maintaining 
the integrity with general skin folding. 
 The folding endurance measures the ability of patch to withstand rupture.   
Drug Content 
 Drug content in each small circular patches were analyzed 
spectrophotometrically and it was observed that all the formulations showed a 
satisfactory drug content values ranging from 88 – 99% ensures the uniform 
reproducible sustained release of the drug from the patch. 
Weight Uniformity 
 From each batch, the weight of five patches was taken on a digital balance. 
It was observed that weight of the entire film sample in each formulation was 
uniform.  
Surface pH 
 The surface pH for all the formulations was well within the optimum range 
of 5-6 and hence no skin irritation was expected to occur after applications of the 
patches. 
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Table 17 Physical characteristics of formulated transdermal patches 
Formulation Formulation 
code 
Evaluation Parameters 
Thickness 
(mm) 
Folding 
endurance 
Drug 
content 
(%) 
Weight 
uniformity 
(mg) 
Surface 
pH 
Almotriptan 
loaded 
HPMC – 
ERS100 
patches 
F A1 0.232 >300 99.85 350 5 
F A2 0.334 >300 98.92 480 5.11 
Almotriptan 
loaded 
HPMC – EC 
patches 
F B1 0.128 >300 95.77 370 5.88 
F B2 0.256 >300 96.8 450 5.24 
Almotriptan 
loaded 
HPMC 
patches 
F C1 0.128 >300 88.58 230 6 
F C2 0.116 >300 94.43 300 6.14 
 
Swellability 
 The percentage of swelling of Almotriptan Malate loaded HPMC K 15M-
ERS 100 patches was around 30 and the other formulations also showed 
considerable swelling. Hydrophilic polymer showed considerable swelling, as it 
increased the surface wettability and consequently water penetration within the 
matrix. 
 In the swelling study it was observed that as time increased, the swelling 
index was also increased, because weight gain by patch was increased 
proportionally with the rate of hydration up to certain time. The  consequence  of  
water  uptake  could  be  the  formation  of  empty  spaces  within  the  patch  that  
could  make  its  structure  less  resistant  to  mechanical  stresses.   
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Percentage Moisture Absorption 
 Percentage moisture absorption for HPMC-ERS 100, HPMC-EC and 
HPMC alone was found in the range of 14.72 %, 9.5 % and 4.94% respectively; 
this may be due to hydrophilic and hydrophobic nature of the polymer. 
 The lower moisture content in the formulations made the patches to remain 
stable and become a completely dried and brittle film and also protects the 
material from microbial contamination and bulkiness (Ashok et al., 2010). 
Percentage Moisture Loss 
 From moisture loss study it was found that formulation showed maximum 
amount of moisture loss due to HPMC K 15M as it undergo moisture loss in dry 
condition. Inspite of the moisture loss, patches were found to maintain their 
physical stability. 
 The low percentages of moisture loss help them to remain stable and free 
from completely drying and brittle (Ashok et al., 2010). 
Water Vapour Transmission Rate 
 Patches having ERS 100 as the hydrophobic polymer showed least 
transmission rate than that of patches with EC. All the formulations were 
permeable to water vapour. Low water vapor transmission rate also indicates high 
degree of stability even in high humid conditions (Ashok et al., 2010). 
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Table 18 Physico-chemical characteristics of formulated transdermal films 
Formulation Formulation 
code 
Evaluation Parameters 
Swellability 
(%) 
% 
Moisture 
Loss (%) 
% 
Moisture 
Absorbed 
(%) 
WVTR 
(g/h/cm2) 
Almotriptan 
loaded 
HPMC – 
ERS100 
patches 
F A1 28.76 6.42 14.72 2.97×10-4 
F A2 30.4 5.4 11.75 3.8×10-4 
Almotriptan 
loaded 
HPMC – EC 
patches 
F B1 16.78 4.35 9.6 5.25 ×10-4 
F B2 20 3.56 5.87 4.7 ×10-4 
Almotriptan 
loaded 
HPMC 
patches 
F C1 20.98 4.28 4.94 5.98 ×10-4 
F C2 29.54 4.51 3.334 6.25 ×10-4 
 
In-Vitro Drug Release Study 
 The  cumulative  percent  drug  release was  higher  in  case  of  Eudragit  
containing  polymer  matrix as it released 3.39 mg/cm2 /12 hrs and 6.08 mg/cm2 
/12 hrs for low dose (6.25 mg) & high dose (12.5 mg) of Almotriptan Malate. The 
reason for high release from ERS 100 polymer  could  be  explained  by  the  
hydrophobic  nature  of  this  polymer  and  the  existence  of  the  quaternary  
ammonium  groups  which  could  affect  the  release  from  the  patches  because  
of  the  hydration  and  swelling  of  the  patches.  Eudragit  (Polymethyl  
methacrylate)  is  known  to  have  larger  cavity size in its polymeric network and 
thus it may involve a faster mode  of  diffusion  of  Almotriptan Malate from  the  
ERS 100: HPMC K 15M  formulations  as  compared  to  the  EC:  HPMC K 15M  
formulations. 
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   Release  of  the  drug  from  transdermal  patches  is  controlled  by  the  
chemical  properties  of  the  drug  and  delivery  form,  as  well  as  physiological  
and  physicochemical  properties  of  the  biological  membrane.  The  process  of  
drug  release  in  most  controlled  release  devices  is  governed  by  diffusion  and  
the  polymer  matrix  has  strong  influence on the diffusivity as the motion of a 
small molecule is restricted   by  the  three‐dimensional  network  of  polymer  
chains.  
Table 19 Cumulative drug release profile for Almotriptan Malate loaded 
HPMC K 15M-ERS 100 patches. 
 
 
Time 
(hr) 
Cumulative Amount of Drug 
Released (mg) 
Cumulative Percentage Amount 
of Drug Released (%) 
Formulation 
A1 
Formulation 
A2 
Formulation 
A1 
Formulation 
A2 
1 0.12 0.19 1.98 1.52 
2 0.25 0.37 4.02 2.99 
3 0.77 1.34 12.33 10.78 
4 1.63 2.54 26.16 20.32 
5 1.89 3.28 30.32 26.31 
6 2.16 3.75 34.64 30.01 
7 2.37 4.00 38.02 32.02 
8 2.62 4.51 42.06 36.12 
9 3.02 5.0 48.32 40.23 
10 3.14 5.5 50.25 44.03 
11 3.26 5.7 52.31 46.2 
12 3.39 6.0 54.26 48.3 
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Table 20 Cumulative drug release profile for Almotriptan Malate loaded 
HPMC K 15M-EC patches 
 
 
Time 
(hr) 
Cumulative Amount of Drug 
Released (mg) 
Cumulative Percentage Amount 
of Drug Released (%) 
Formulation 
B1 
Formulation 
B2 
Formulation 
B1 
Formulation 
B2 
1 0.12 0.22 1.86 1.82 
2 0.31 0.45 4.96 3.62 
3 0.67 1.04 10.86 8.38 
4 1.58 2.79 25.32 22.32 
5 1.92 3.58 30.85 28.68 
6 2.02 3.91 32.32 31.33 
7 2.41 4.27 38.62 34.23 
8 2.56 5.07 41 40.62 
9 2.73 5.14 43.68 41.12 
10 2.85 5.27 45.63 42.23 
11 2.89 5.44 46.32 43.52 
12 2.97 5.54 47.63 44.35 
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Table 21 Cumulative drug release profile for Almotriptan Malate loaded 
HPMC K 15M patches 
Time 
(hr) 
Cumulative Amount of Drug 
Released (mg) 
Cumulative Percentage Amount 
of Drug Released (%) 
Formulation 
C1 
Formulation 
C2 
Formulation 
C1 
Formulation 
C2 
1 0.08 0.16 1.37 1.28 
2 0.21 0.4 3.46 3.2 
3 0.39 0.535 6.28 4.28 
4 0.98 1.765 15.68 14.12 
5 1.40 2.27 22.45 18.18 
6 1.58 2.53 25.32 20.25 
7 1.68 3.02 26.98 24.23 
8 2.12 3.5 33.98 28.12 
9 2.45 4.01 39.29 32.12 
10 2.51 4.27 40.25 34.23 
11 2.66 4.79 42.68 38.32 
12 2.83 5.16 45.36 41.28 
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Graph 6 Cumulative drug release profile for Almotriptan Malate loaded 
HPMC K 15M-ERS 100 patches 
 
Graph 7 Cumulative drug release profile for Almotriptan Malate loaded  
HPMC K 15M-EC patches 
 
Graph 8 Cumulative drug release profile for Almotriptan Malate loaded 
HPMC K 15M patches 
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EXPERIMENTAL STATISTICAL DESIGN  
 The aim of present work was to achieve optimized formulations for 
Almotriptan loaded transdermal patches by determining the effects of some 
important factors (variables) and their interactions during the process of 
preparation. Among all combinations HPMC K 15M:ERS 100 loaded with 
Almotriptan Malate gave better results. Hence these formulations were selected 
and incorporated in 22 factorial design and evaluated for further studies. Two of 
the most significant factors (concentration of HPMC K 15M and ERS 100) had 
been chosen as the independent variables. In the next step, for determining the low 
and high levels of each factor, some formulations were made. According to a 22 
factorial design and considering these two variables, 4 experiments each for low 
and high doses of Almotriptan had been performed. The effect of these variables 
on drug content, moisture absorption, moisture loss and cumulative amount of 
drug release at 12 hr were investigated as optimization response parameters in the 
current study. 
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Table 22 22 full factorial experimental design layout for low dose (6.25 mg) of 
Almotriptan Malate 
Formulation 
Code 
HPMC 
K 15M 
(mg) 
(A) 
E 
RS100 
(mg) 
(B) 
Drug 
Content 
(%) 
Moisture 
Absorption 
(%) 
Moisture 
Loss 
(%) 
Cumulative 
% Drug 
Release 
At 12hr 
(%) 
F1 600 400 98.89 13.36 7.42 45.50 
F2 400 600 99.85 14.72 6.42 54.26 
F3 600 600 99.90 16.8 8.6 45.71 
F4 400 400 99.00 10.43 5.432 50.33 
 
Table 23 22 full factorial experimental design layout for high dose (12.5 mg) 
of Almotriptan Malate 
Formulation 
Code 
HPMC 
K 15M 
(mg) 
(A) 
E 
RS100 
(mg) 
(B) 
Drug 
Content 
(%) 
Moisture 
Absorption 
(%) 
Moisture 
Loss 
(%) 
Cumulative 
% Drug 
Release 
At 12hr(%) 
F5 600 400 97.90 15.9 6.1 36.80 
F6 400 600 98.92 11.75 5.4 48.30 
F7 600 600 98.90 17.4 7.9 39.56 
F8 400 400 98.20 10.56 3.9 44.72 
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The polynomial equations for the dependent responses of low dose (6.25 mg) 
of Almotriptan Malate are as follows: 
Drug 
content 
= 98.16 - 0.002150 HPMC K 15M + 0.002650 ERS 100 
+ 0.000004 HPMC K 15M*ERS 100 
Moisture 
absorption 
= -7.410 + 0.02315 HPMC K 15M + 0.02995 ERS 100 
- 0.000021 HPMC K 15M*ERS 100 
Moisture 
loss 
= 0.2480 + 0.008020 HPMC K 15M + 0.003020 ERS 100 
+ 0.000005 HPMC K 15M*ERS 100 
Cumulative 
% drug 
release 
= 37.25 + 0.01305 HPMC K 15M + 0.05685 ERS 100 
- 0.000093 HPMC K 15M*ERS 100 
 
 
The polynomial equations for the dependent responses of high dose (12.5 mg) 
of Almotriptan Malate are as follows: 
Drug content = 98.48 - 0.004300 HPMC K 15M + 0.000800 ERS 100 
+ 0.000007 HPMC K 15M*ERS 100 
Moisture 
absorption 
= -1.260 + 0.02360 HPMC K 15M + 0.002850 ERS 100 
+ 0.000008 HPMC K 15M*ERS 100 
Moisture loss  = -2.300 + 0.008000 HPMC K 15M + 0.004500 ERS 100 
+ 0.000007 HPMC K 15M*ERS 100 
Cumulative 
% drug 
released 
= 50.12 - 0.03140 HPMC K 15M + 0.02610 ERS 100 
- 0.000020 HPMC K 15M*ERS 100 
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Fig.13 : Surface Plot for low Dose (6.25 mg) of Almotriptan Malate 
  
             
 
 
 
 
 
 
Fig.14 : Surface Plot for high dose ( 12.5 mg) of Almotriptan Malate 
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EFFECT ON AGING 
 Transdermal patches of the best formulated Almotriptan Malate patches 
was found to be physically and chemically stable and showed no significant 
change in terms of physical characteristics, surface pH, folding endurance, 
percentage drug content and percentage drug release. It is evident from the 
stability study that the films are stable under normal shelf-conditions. There were 
no significant physical and chemical changes in the optimized batch after  
2 months. Elasticity of patches was found to be maintained. 
 
Table 24 % drug content & % cumulative drug release during stability study 
Time in days 
% drug content % cumulative drug release 
at 12hr 
Formulation 
A1 
Formulation 
A2 
Formulation 
A1 
Formulation 
A2 
0 99.85 98.92 54.26 48.3 
30 99.79 98.80 54.20 48 
60 99 99.30 53 47.6 
 
In- Vitro Drug Release Kinetics Study 
 It was observed that the best formulation i.e. that of Almotriptan Malate 
loaded HPMC K 15M-ERS 100 followed the zero order kinetics. The correlation 
coefficient (R) values were higher in zero order model when compared to other 
order model.  So, it was concluded that this formulation follows zero order 
kinetics, which release drug in control manner and it is the ideal method of drug 
release to achieve pharmacological prolonged action. 
 In order to determine the release mechanism that provides the best 
description to the pattern of drug release, the in vitro release data were fitted to 
zero order, first order, and Higuchi matrix. The release data were also kinetically 
analyzed using the Korsemeyer–Peppas model. 
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The release exponent (n) describing the mechanism of drug release from the 
matrices was calculated by regression analysis using the following equation. 
Mt/ M∞ = Ktn 
 Where Mt / M∞ is a fraction of drug released at time t, k is the release rate 
constant and n is the release exponent. For both the formulations the values of 
release exponent “n” obtained by applying Peppas equation was greater than 0.45, 
thus it was observed that the mechanism of drug release was Non Fickian 
diffusion, the type of release was anomalous transport. 
 The n value is used to characterize different release, 0.45 ≤ n corresponds 
to a Fickian diffusion mechanism, 0.45 < n < 0.89 to non-Fickian transport 
(anomalous), n = 0.89 to Case II  transport, and n > 0.89 to Super Case II 
transport. 
Table 25 Drug release kinetics data of FA1 
Formulation A1 
Time 
(hr) 
Square 
root of 
time 
Log time 
Cumulative 
amount of 
drug released 
Cumulative 
% amount 
of drug 
released 
Log 
cumulative 
% amount 
of drug 
released 
1 1 0 0.12 1.98 0.2966 
2 1.4142 0.3010 0.25 4.02 0.60422 
3 1.7320 0.4771 0.77 12.33 1.0909 
4 2 0.6020 1.63 26.16 1.4176 
5 2.2360 0.6989 1.89 30.32 1.4817 
6 2.4494 0.7781 2.16 34.64 1.5395 
7 2.6457 0.8450 2.37 38.02 1.5800 
8 2.8284 0.9030 2.62 42.06 1.6238 
9 3 0.9542 3.02 48.32 1.6841 
10 3.1622 1 3.14 50.25 1.7011 
11 3.3166 1.0413 3.26 52.31 1.7185 
12 3.4641 1.0791 3.39 54.26 1.7344 
 
Results & Discussions 
 
 
 
Department of Pharmaceutics   89 
Table 26 Drug release Kinetics data of FA2 
Formulation A2 
Time 
(hr) 
Square 
root of 
time 
Log time 
Cumulative 
amount of 
drug 
released 
Cumulative 
% amount of 
drug 
released 
Log 
cumulative 
% amount 
of drug 
released 
1 1 0 0.19 1.52 0.1818 
2 1.4142 0.3010 0.37 2.99 0.4756 
3 1.7320 0.4771 1.34 10.78 1.03261 
4 2 0.6020 2.54 20.32 1.3079 
5 2.2360 0.6989 3.28 26.31 1.4201 
6 2.4494 0.7781 3.75 30.01 1.4772 
7 2.6457 0.8450 4.00 32.02 1.5054 
8 2.8284 0.9030 4.51 36.12 1.5577 
9 3 0.9542 5.0 40.23 1.6045 
10 3.1622 1 5.5 44.03 1.6437 
11 3.3166 1.0413 5.7 46.2 1.6646 
12 3.4641 1.0791 6.0 48.3 1.6839 
 
Table 27 Release kinetic modeling of drug release 
Formulation 
code 
Regression Constant Value (R2) 
n 
value Zero 
Order 
First 
Order 
Higuchi’s 
Model 
 
Korsemeyer 
Peppas 
Model 
A1 0.9462 0.5855 0.6265 0.9250 0.631 
A2 0.9674 0.6592 0.6137 0.9457 0.704 
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Graph 9 Zero order plot for FA1  Graph 10 First order plot for FA1 
 
Graph 11 Higuchis plot for FA1    Graph 12 Korsemeyer-Peppas plot for FA1 
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Graph 13 Zero order plot for FA2  Graph 14 First order plot for FA2 
            
Graph 15 Higuchis plot for FA2   Graph16 Korsemeyer-Pepppas plot for  
        FA2 
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SUMMARY & CONCLUSION 
 Transdermal delivery represents an attractive alternative to oral drug 
delivery. TDDS has been accepted as a potential non invasive route of drug 
administration, with advantages of prolonged therapeutic effect, reduced side 
effects, improved bioavailability, better patient compliance and easy termination 
of drug therapy. Thus it is anticipated that TDDS, the most suitable system for a 
long term treatment or for a multi –dose treatment can be designed to deliver drug 
at appropriate rates to maintain suitable plasma drug levels for the therapeutic 
efficacy by using skin as the port of entry of drugs. 
 Almotriptan Malate, the highly selective serotonin 5-HT1B/1D receptor 
agonist, used in the acute treatment of moderate to severe migraine attacks in 
adults and adolescent patients with a history of migraine with or without aura, is 
reported to have the best sustained pain-free rate and the lowest adverse events 
rate of all the triptans. Furthermore, it is well known that Almotriptan Malate 
involves a much lower risk of adverse events than Sumatriptan, Zolmitriptan and 
Rizatriptan, making it a better tolerated and more cost-effective choice for triptan-
naïve patients and thus making interest in the development of a new route for the 
therapeutic administration of this drug. 
 So the present research work was aimed to develop matrix type 
transdermal patches of Almotriptan Malate using polymers HPMC K 15M, ERS 
100 and EC and plasticizers DBP & PEG 400 via solvent casting method for low 
dose (6.25 mg) & high dose (12.5 mg) of drug. This formulation would help to 
avoid non-compliance of the tablet dosage form. 
 The spectra of drug and physical mixtures of drug-polymers were taken by 
using FTIR spectrophotometer and confirmed the absence of incompatibility 
between drug (Almotriptan Malate) and the physical mixture of polymers (HPMC 
K15M, ERS 100 and EC). Thus, concluded that Almotriptan Malate can be 
formulated in to a transdermal patch with the above mentioned polymers. 
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 Incorporation of plasticizer at an optimum concentration yielded smooth 
and flexible patches. There were no significant difference in thickness and average 
weight among each group and thus indicated that the patches were uniform 
throughout. Surface pH of all the films were found to be in the range of 5-6, 
indicating that irritation will not occur on the skin after applications of the 
patches. 
 Swellability of the patches due to presence of polymer was measured by its 
weight gain or water uptake and the transdermal patches showed good swelling 
and maintained the integrity of formulation which is required for bio-adhesion. 
The quantity of moisture transmitted through unit area of a patch in unit time 
found out, helped us to know the permeation characteristics. Low water vapor 
transmission rate also indicates high degree of stability even in high humid 
conditions. 
 
 To check the moisture sensitiveness of the patch during their storage, 
percentage moisture loss test was carried out & to check the physical stability and 
integrity of the films at high humid conditions, percentage moisture absorption 
test was carried out. The low percentages of moisture loss and moisture absorption 
helps the patches to remain stable and free from completely drying and brittle and 
also protect the patches from microbial contamination. 
 
 Based on in-vitro drug studies, Almotriptan Malate loaded with polymers 
HPMC K 15M-ERS 100 with DBP as plasticizer was considered as the best 
formulation, in both high and low doses of drug, (6.25 mg & 12.5 mg) which 
exhibited the drug release of 3.39 mg/cm2 /12 hrs and 6.08 mg/cm2 /12 hrs 
respectively. The patches were found to be stable for 2 months with respect to 
Almotriptan Malate content and there was no significant change in physico-
chemical and drug release characteristics of the films. 
 The present study demonstrated the optimization of Almotriptan Malate 
loaded transdermal patches by statistical 2 level 2 factorial design using 
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Minitab18 software.  The independent variables selected were HPMC K 15M and 
ERS 100. The effect of these variables on drug content, %moisture absorption, 
%moisture loss and cumulative % drug release at 12hr were investigated as 
optimization response parameters in the current study. It provides flexibility and 
giving importance for each response individually. Optimization aided in 
understanding the interaction of formulation parameters, which can be 
exemplified by increase in both the polymer concentration decreases drug release 
and it was found that concentration of HPMC K 15M were found to have 
individual effect on moisture uptake and loss i.e. when its concentration increased 
moisture absorption and loss also increased. 
 Release data were analyzed as per the zero order model, first order model, 
Higuchi model, and Korsemeyer-Peppas model to assess the drug release kinetics 
and mechanism from the patches. Analysis of the release data as per zero order 
and first order kinetic models indicated that the drug release from TDDS patches 
formulated followed zero order kinetics. The correlation coefficient values were 
higher in zero order model when compared to first order model.   When the 
release data were analyzed as per Peppas equation, the release exponent ‘n’, used 
to characterize different release mechanisms was found in the range 0.45- 0.89 in 
the case of TDDS patches indicating non-fickian (anomalous) diffusion as the 
release mechanism from these patches.  
 From the present investigation, it may be concluded that such matrix type 
transdermal patches of Almotriptan Malate may provide sustained transdermal 
delivery for prolonged periods in the management of migraine, which can be a 
good way to bypass the extensive hepatic first pass metabolism. The result of the 
study showed the feasibility of formulating rate-controlled transdermal films of 
Almotriptan Malate for effective control and prophylaxis of migraine. Further in-
vivo investigations are required to correlate in-vitro permeation studies for the 
development of suitable transdermal system of Almotriptan Malate. 
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